2024
Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer. (Journal article)
Malla, S. B., Byrne, R. M., Lafarge, M. W., Corry, S. M., Fisher, N. C., Tsantoulis, P. K., . . . Dunne, P. D. (2024). Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.. Nature genetics, 56(6), 1321. doi:10.1038/s41588-024-01809-4DOI: 10.1038/s41588-024-01809-4
Karapetis, C. S., Liu, H., Sorich, M. J., Pederson, L. D., Van Cutsem, E., Maughan, T., . . . Shi, Q. (2024). Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.. British journal of cancer, 130(8), 1269-1278. doi:10.1038/s41416-024-02604-yDOI: 10.1038/s41416-024-02604-y
Harris, B. H. L., Di Giovannantonio, M., Zhang, P., Harris, D. A., Lord, S. R., Allen, N. E., . . . Buffa, F. M. (2024). New role of fat-free mass in cancer risk linked with genetic predisposition.. Scientific reports, 14(1), 7270. doi:10.1038/s41598-024-54291-7DOI: 10.1038/s41598-024-54291-7
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer. (Journal article)
Malla, S. B., Byrne, R. M., Lafarge, M. W., Corry, S. M., Fisher, N. C., Tsantoulis, P. K., . . . Dunne, P. D. (2024). Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.. Nature genetics, 56(3), 458-472. doi:10.1038/s41588-024-01654-5DOI: 10.1038/s41588-024-01654-5
Javed, S. R., Lord, S., El Badri, S., Harman, R., Holmes, J., Kamzi, F., . . . Hawkins, M. A. (2024). CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.. British journal of cancer, 130(3), 467-475. doi:10.1038/s41416-023-02542-1DOI: 10.1038/s41416-023-02542-1
7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis (Journal article)
Raeisi, M., Cohen, R., Chibaudel, B., Hurwitz, H., Saltz, L., Kabbinavar, F., . . . De Gramont, A. (2024). 7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis. ESMO Open, 9, 102262. doi:10.1016/j.esmoop.2024.102262DOI: 10.1016/j.esmoop.2024.102262
2023
Beach, C., MacLean, D., Majorova, D., Melemenidis, S., Nambiar, D. K., Kim, R. K., . . . Olcina, M. M. (2023). Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.. The Journal of clinical investigation, 133(23), e168277. doi:10.1172/jci168277DOI: 10.1172/jci168277
A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR) (Journal article)
O'Cathail, S. M., Qiao, M., Muirhead, R., Adams, R., Rao, S., Fisher, K., . . . Hawkins, M. A. (2023). A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR). International Journal of Radiation Oncology*Biology*Physics, 117(2), e329-e330. doi:10.1016/j.ijrobp.2023.06.2379DOI: 10.1016/j.ijrobp.2023.06.2379
Modeling Acute Chemoradiotherapy (CRT) Diarrhea Severity Using Automatically Contoured Small Bowel (Journal article)
Shen, Z., Brand, D., Zhang, Y., Simard, M., Lopes, A., Miles, E., . . . Hawkins, M. A. (2023). Modeling Acute Chemoradiotherapy (CRT) Diarrhea Severity Using Automatically Contoured Small Bowel. International Journal of Radiation Oncology*Biology*Physics, 117(2), e338. doi:10.1016/j.ijrobp.2023.06.2397DOI: 10.1016/j.ijrobp.2023.06.2397
Teoh, S., Ooms, A., George, B., Owens, R., Chu, K. -Y., Drabble, J., . . . Mukherjee, S. (2023). Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK.. BMJ open, 13(9), e068906. doi:10.1136/bmjopen-2022-068906DOI: 10.1136/bmjopen-2022-068906
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. (Journal article)
Katipally, R. R., Martinez, C. A., Pugh, S. A., Bridgewater, J. A., Primrose, J. N., Domingo, E., . . . with the S:CORT Consortium. (2023). Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.. JAMA oncology, 9(9), 1245-1254. doi:10.1001/jamaoncol.2023.2535DOI: 10.1001/jamaoncol.2023.2535
Richman, S. D., Hemmings, G., Roberts, H., Gallop, N., Dodds, R., Wilkinson, L., . . . Adams, R. (2023). FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.. Journal of clinical pathology, 76(8), 548-554. doi:10.1136/jclinpath-2022-208233DOI: 10.1136/jclinpath-2022-208233
Mukherjee, S., Hurt, C. N., Adams, R., Bateman, A., Bradley, K. M., Bridges, S., . . . Crosby, T. D. L. (2023). Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial.. EClinicalMedicine, 61, 102059. doi:10.1016/j.eclinm.2023.102059DOI: 10.1016/j.eclinm.2023.102059
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity. (Journal article)
Palles, C., Lucas, M., Watts, K., Galavotti, S., Chin, I. S., Campbell, C., . . . Cheadle, J. (2023). A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.. Journal of Clinical Oncology, 41(16_suppl), 3028. doi:10.1200/jco.2023.41.16_suppl.3028DOI: 10.1200/jco.2023.41.16_suppl.3028
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. (Journal article)
Pugh, S. A., Domingo, E., Richman, S. D., Dunne, P. D., Redmond, K., Blake, A., . . . Bridgewater, J. A. (2023). Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.. Journal of Clinical Oncology, 41(16_suppl), 3577. doi:10.1200/jco.2023.41.16_suppl.3577DOI: 10.1200/jco.2023.41.16_suppl.3577
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). (Journal article)
Kopetz, S., Yoshino, T., Kim, T. W., Wasan, H. S., Van Cutsem, E., Ciardiello, F., . . . Tabernero, J. (2023). BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 41(16_suppl), TPS3627. doi:10.1200/jco.2023.41.16_suppl.tps3627DOI: 10.1200/jco.2023.41.16_suppl.tps3627
Wills, C., Watts, K., Maughan, T. S., Fisher, D., Al-Tassan, N. A., Houlston, R. S., . . . Cheadle, J. P. (2023). Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.. Genes, chromosomes & cancer, 62(6), 332-341. doi:10.1002/gcc.23133DOI: 10.1002/gcc.23133
Next generation radiotheranostics promoting precision medicine. (Journal article)
Pomykala, K. L., Hadaschik, B. A., Sartor, O., Gillessen, S., Sweeney, C. J., Maughan, T., . . . Herrmann, K. (2023). Next generation radiotheranostics promoting precision medicine.. Annals of oncology : official journal of the European Society for Medical Oncology, 34(6), 507-519. doi:10.1016/j.annonc.2023.03.001DOI: 10.1016/j.annonc.2023.03.001
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. (Journal article)
Cohen, R., Raeisi, M., Shi, Q., Chibaudel, B., Yoshino, T., Zalcberg, J. R., . . . De Gramont, A. (2023). Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.. Journal of Clinical Oncology, 41(16_suppl), 3554. doi:10.1200/jco.2023.41.16_suppl.3554DOI: 10.1200/jco.2023.41.16_suppl.3554
OC-0103 SCOPE2 PET: continuing CisCap v switch to CarPac in PET non-responders on dCRT for esophageal cancer (Journal article)
Mukherjee, S., Hurt, C., Gwynne, S., Nixon, L., Bridges, S., Adams, R., . . . Crosby, T. (2023). OC-0103 SCOPE2 PET: continuing CisCap v switch to CarPac in PET non-responders on dCRT for esophageal cancer. Radiotherapy and Oncology, 182, S64-S65. doi:10.1016/s0167-8140(23)08517-1DOI: 10.1016/s0167-8140(23)08517-1
Punt, C. J. A., Heinemann, V., Maughan, T., Cremolini, C., Van Cutsem, E., McDermott, R., . . . Pfeiffer, P. (2023). Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.. ESMO open, 8(2), 101199. doi:10.1016/j.esmoop.2023.101199DOI: 10.1016/j.esmoop.2023.101199
Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. (Journal article)
Fernandez-Rozadilla, C., Timofeeva, M., Chen, Z., Law, P., Thomas, M., Schmit, S., . . . Peters, U. (2023). Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries.. Nature genetics, 55(3), 519-520. doi:10.1038/s41588-023-01334-wDOI: 10.1038/s41588-023-01334-w
Samant, P., Ruysscher, D. D., Hoebers, F., Canters, R., Hall, E., Nutting, C., . . . Van den Heuvel, F. (2023). Machine learning for normal tissue complication probability prediction: Predictive power with versatility and easy implementation.. Clinical and translational radiation oncology, 39, 100595. doi:10.1016/j.ctro.2023.100595DOI: 10.1016/j.ctro.2023.100595
Begum, M., Lewison, G., Wang, X., Dunne, P. D., Maughan, T., Sullivan, R., & Lawler, M. (2023). Global colorectal cancer research, 2007-2021: Outputs and funding.. International journal of cancer, 152(3), 470-479. doi:10.1002/ijc.34279DOI: 10.1002/ijc.34279
Flanagan, D. J., Amirkhah, R., Vincent, D. F., Gunduz, N., Gentaz, P., Cammareri, P., . . . Sansom, O. J. (2023). Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.. Nature communications, 14(1), 522. doi:10.1038/s41467-023-36266-wDOI: 10.1038/s41467-023-36266-w
Fernandez-Rozadilla, C., Timofeeva, M., Chen, Z., Law, P., Thomas, M., Schmit, S., . . . Peters, U. (2023). Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries.. Nature genetics, 55(1), 89-99. doi:10.1038/s41588-022-01222-9DOI: 10.1038/s41588-022-01222-9
Joint Prediction of Response to Therapy, Molecular Traits, and Spatial Organisation in Colorectal Cancer Biopsies (Conference Paper)
Wood, R., Domingo, E., Sirinukunwattana, K., Lafarge, M. W., Koelzer, V. H., Maughan, T. S., & Rittscher, J. (2023). Joint Prediction of Response to Therapy, Molecular Traits, and Spatial Organisation in Colorectal Cancer Biopsies. In Unknown Conference (pp. 758-767). Springer Nature Switzerland. doi:10.1007/978-3-031-43904-9_73DOI: 10.1007/978-3-031-43904-9_73
Wills, C., Houseman, A., Watts, K., Maughan, T. S., Fisher, D., Houlston, R. S., . . . Cheadle, J. P. (2023). Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease.. BJC reports, 1(1), 2. doi:10.1038/s44276-023-00003-zDOI: 10.1038/s44276-023-00003-z
2022
Flanagan, D. J., Amirkhah, R., Vincent, D. F., Gunduz, N., Gentaz, P., Cammareri, P., . . . Sansom, O. J. (2022). Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.. Nature communications, 13(1), 7551. doi:10.1038/s41467-022-35134-3DOI: 10.1038/s41467-022-35134-3
Corry, S. M., McCorry, A. M., Lannagan, T. R., Leonard, N. A., Fisher, N. C., Byrne, R. M., . . . Dunne, P. D. (2022). Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.. Gut, 71(12), 2502-2517. doi:10.1136/gutjnl-2021-326183DOI: 10.1136/gutjnl-2021-326183
Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT (Journal article)
Brown, L. C., Fisher, D., Adams, R., Seligmann, J., Seymour, M., Kaplan, R., . . . Maughan, T. S. (2022). Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT.
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia. (Journal article)
Gil Vazquez, E., Nasreddin, N., Valbuena, G. N., Mulholland, E. J., Belnoue-Davis, H. L., Eggington, H. R., . . . Leedham, S. J. (2022). Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.. Cell stem cell, 29(11), 1612. doi:10.1016/j.stem.2022.09.005DOI: 10.1016/j.stem.2022.09.005
Dosimetric Impact of Gastrointestinal Tract Variability during Online Adaptive MR-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas (Journal article)
Teoh, S., George, B., Owens, R., Bungay, H., Maughan, T. S., & Mukherjee, S. (2022). Dosimetric Impact of Gastrointestinal Tract Variability during Online Adaptive MR-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas. International Journal of Radiation Oncology*Biology*Physics, 114(3), e599. doi:10.1016/j.ijrobp.2022.07.2293DOI: 10.1016/j.ijrobp.2022.07.2293
Spurr, L. F., Martinez, C. A., Katipally, R. R., Iyer, S. C., Pugh, S. A., Bridgewater, J. A., . . . Pitroda, S. P. (2022). A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy.. NPJ precision oncology, 6(1), 72. doi:10.1038/s41698-022-00318-zDOI: 10.1038/s41698-022-00318-z
Hashimoto, T., Takayanagi, D., Yonemaru, J., Naka, T., Nagashima, K., Yatabe, Y., . . . Sekine, S. (2022). Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.. British journal of cancer, 127(6), 1043-1050. doi:10.1038/s41416-022-01880-wDOI: 10.1038/s41416-022-01880-w
Fisher, N. C., Byrne, R. M., Leslie, H., Wood, C., Legrini, A., Cameron, A. J., . . . Dunne, P. D. (2022). Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data.. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(18), 4056-4069. doi:10.1158/1078-0432.ccr-22-1102DOI: 10.1158/1078-0432.ccr-22-1102
Watts, K., Wills, C., Madi, A., Palles, C., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2022). Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.. International journal of cancer, 151(6), 957-966. doi:10.1002/ijc.34046DOI: 10.1002/ijc.34046
Love, S. B., Cafferty, F., Snowdon, C., Carty, K., Savage, J., Pallmann, P., . . . Sydes, M. R. (2022). Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.. Trials, 23(1), 757. doi:10.1186/s13063-022-06680-4DOI: 10.1186/s13063-022-06680-4
337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials (Journal article)
Hassanieh, S., Domingo, E., Blake, A., Fisher, D., Redmond, K. L., Richman, S. D., . . . Maughan, T. (2022). 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. Annals of Oncology, 33, S691. doi:10.1016/j.annonc.2022.07.475DOI: 10.1016/j.annonc.2022.07.475
LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) (Journal article)
Tabernero, J., Yoshino, T., Kim, T. W., Yaeger, R., Desai, J., Wasan, H. S., . . . Kopetz, S. (2022). LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). Annals of Oncology, 33, S1392-S1393. doi:10.1016/j.annonc.2022.08.022DOI: 10.1016/j.annonc.2022.08.022
Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. (Journal article)
Henderson, R. H., French, D., McFerran, E., Adams, R., Wasan, H., Glynne-Jones, R., . . . Lawler, M. (2022). Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer.. Journal of cancer policy, 33, 100342. doi:10.1016/j.jcpo.2022.100342DOI: 10.1016/j.jcpo.2022.100342
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia. (Journal article)
Vasquez, E. G., Nasreddin, N., Valbuena, G. N., Mulholland, E. J., Belnoue-Davis, H. L., Eggington, H. R., . . . Leedham, S. J. (2022). Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.. Cell stem cell, 29(8), 1213-1228.e8. doi:10.1016/j.stem.2022.07.008DOI: 10.1016/j.stem.2022.07.008
Importance of clinical research for the UK's 10-year cancer plan (Journal article)
Lee, R. W., Danson, S., Elliot, M., Park, E. I., Pinkney, T. D., Shaw, C. E., . . . Wadsley, J. (2022). Importance of clinical research for the UK's 10-year cancer plan. LANCET ONCOLOGY, 23(8), 975-978. doi:10.1016/S1470-2045(22)00292-3DOI: 10.1016/S1470-2045(22)00292-3
Goldberg, R. M., Adams, R., Buyse, M., Eng, C., Grothey, A., André, T., . . . de Gramont, A. (2022). Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.. Journal of the National Cancer Institute, 114(6), 819-828. doi:10.1093/jnci/djab218DOI: 10.1093/jnci/djab218
Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture (Preprint)
DOI: 10.1101/2022.06.11.495729
Van den Heuvel, F., Vella, A., Fiorini, F., Brooke, M., Hill, M., Ryan, A., . . . Giaccia, A. (2022). Using oxygen dose histograms to quantify voxelised ultra-high dose rate (FLASH) effects in multiple radiation modalities.. Physics in medicine and biology, 67(12). doi:10.1088/1361-6560/ac71efDOI: 10.1088/1361-6560/ac71ef
First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis. (Journal article)
Shmueli, E. S., Raeisi, M., Chibaudel, B., Maughan, T. S., Douillard, J. -Y., Van Cutsem, E., . . . De Gramont, A. (2022). First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. Journal of Clinical Oncology, 40(16_suppl), 3578. doi:10.1200/jco.2022.40.16_suppl.3578DOI: 10.1200/jco.2022.40.16_suppl.3578
Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis. (Journal article)
Jin, Z., Dixon, J. G., Hubbard, J. M., Eng, C., Lieu, C. H., Douillard, J. -Y., . . . Shi, Q. (2022). Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. Journal of Clinical Oncology, 40(16_suppl), 3572. doi:10.1200/jco.2022.40.16_suppl.3572DOI: 10.1200/jco.2022.40.16_suppl.3572
OC-0103 SCALOP2:A multicenter randomized trial of RT dose escalation and nelfinavir in pancreatic cancer (Journal article)
Mukherjee, S., Qi, C., Shaw, R., Bridgewater, J., Radhakrishna, G., Patel, N., . . . Corrie, P. (2022). OC-0103 SCALOP2:A multicenter randomized trial of RT dose escalation and nelfinavir in pancreatic cancer. Radiotherapy and Oncology, 170, S77-S78. doi:10.1016/s0167-8140(22)02479-3DOI: 10.1016/s0167-8140(22)02479-3
PO-1755 Machine Learning in NTCP prediction --- A superior alternative to the Lyman-Burman-Kutcher model (Journal article)
Samant, P., Maughan, T., Van Den Heuvel, F., Canters, R., Hoebers, F., Hall, E., . . . de Ruysscher, D. (2022). PO-1755 Machine Learning in NTCP prediction --- A superior alternative to the Lyman-Burman-Kutcher model. Radiotherapy and Oncology, 170, S1558-S1560. doi:10.1016/s0167-8140(22)03719-7DOI: 10.1016/s0167-8140(22)03719-7
Reply to A. Kurreck et al and M.S. Copur et al. (Journal article)
Adams, R., Wilson, R., Brown, L., & Maughan, T. (2022). Reply to A. Kurreck et al and M.S. Copur et al.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(11), 1263-1264. doi:10.1200/jco.21.02806DOI: 10.1200/jco.21.02806
Brown, L. C., Graham, J., Fisher, D., Adams, R., Seligmann, J., Seymour, M., . . . FOCUS4 Trial Investigators. (2022). Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.. Clinical trials (London, England), 19(2), 146-157. doi:10.1177/17407745211069879DOI: 10.1177/17407745211069879
Practical Guidance for Running Late-Phase Platform Protocols for Clinical Trials: Lessons From Experienced UK Clinical Trials Units (Preprint)
DOI: 10.21203/rs.3.rs-1195468/v1
Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. (Journal article)
Papamichael, D., Lopes, G. S., Olswold, C. L., Douillard, J. -Y., Adams, R. A., Maughan, T. S., . . . Shi, Q. (2022). Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.. European journal of cancer (Oxford, England : 1990), 163, 1-15. doi:10.1016/j.ejca.2021.12.007DOI: 10.1016/j.ejca.2021.12.007
Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data. (Journal article)
Ahmaderaghi, B., Amirkhah, R., Jackson, J., Lannagan, T. R. M., Gilroy, K., Malla, S. B., . . . Dunne, P. D. (2022). Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data.. Disease models & mechanisms, 15(3), dmm049257. doi:10.1242/dmm.049257DOI: 10.1242/dmm.049257
Enhancing Local Context of Histology Features in Vision Transformers (Conference Paper)
Wood, R., Sirinukunwattana, K., Domingo, E., Sauer, A., Lafarge, M. W., Koelzer, V. H., . . . Rittscher, J. (2022). Enhancing Local Context of Histology Features in Vision Transformers. In Unknown Conference (pp. 154-163). Springer Nature Switzerland. doi:10.1007/978-3-031-19660-7_15DOI: 10.1007/978-3-031-19660-7_15
2021
Wills, C., He, Y., Summers, M. G., Lin, Y., Phipps, A. I., Watts, K., . . . Cheadle, J. P. (2021). A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.. European journal of cancer (Oxford, England : 1990), 159, 247-258. doi:10.1016/j.ejca.2021.09.047DOI: 10.1016/j.ejca.2021.09.047
Jones, H. J. S., Cunningham, C., Askautrud, H. A., Danielsen, H. E., Kerr, D. J., Domingo, E., . . . Koelzer, V. H. (2021). Stromal composition predicts recurrence of early rectal cancer after local excision.. Histopathology, 79(6), 947-956. doi:10.1111/his.14438DOI: 10.1111/his.14438
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. (Journal article)
Yin, J., Cohen, R., Jin, Z., Liu, H., Pederson, L., Adams, R., . . . Lenz, H. -J. (2021). Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.. Journal of the National Cancer Institute, 113(12), 1705-1713. doi:10.1093/jnci/djab112DOI: 10.1093/jnci/djab112
Adams, R. A., Fisher, D. J., Graham, J., Seligmann, J. F., Seymour, M., Kaplan, R., . . . FOCUS4 Trial Investigators. (2021). Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(33), 3693-3704. doi:10.1200/jco.21.01436DOI: 10.1200/jco.21.01436
Seligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., . . . FOCUS4 Trial Investigators. (2021). Inhibition of WEE1 Is Effective in <i>TP53</i>- and <i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(33), 3705-3715. doi:10.1200/jco.21.01435DOI: 10.1200/jco.21.01435
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. (Journal article)
Watts, K., Wills, C., Madi, A., Palles, C., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2021). Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.. International journal of cancer, 149(9), 1713-1722. doi:10.1002/ijc.33739DOI: 10.1002/ijc.33739
Modelling of Dosimetric Impact of Visceral Organ Variability During MRI-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas. (Journal article)
Teoh, S., Chu, K. Y., Robinson, M., Whyntie, T., Heuvel, F. V. D., Mukherjee, S., & Maughan, T. S. (2021). Modelling of Dosimetric Impact of Visceral Organ Variability During MRI-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas.. International journal of radiation oncology, biology, physics, 111(3S), e556-e557. doi:10.1016/j.ijrobp.2021.07.1508DOI: 10.1016/j.ijrobp.2021.07.1508
Ten Hoorn, S., Sommeijer, D. W., Elliott, F., Fisher, D., de Back, T. R., Trinh, A., . . . Vermeulen, L. (2021). Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.. British journal of cancer, 125(8), 1080-1088. doi:10.1038/s41416-021-01477-9DOI: 10.1038/s41416-021-01477-9
BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. (Journal article)
Cohen, R., Liu, H., Fiskum, J., Adams, R., Chibaudel, B., Maughan, T. S., . . . André, T. (2021). BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.. Journal of the National Cancer Institute, 113(10), 1386-1395. doi:10.1093/jnci/djab042DOI: 10.1093/jnci/djab042
Chromosomal instability mediates immune exclusion and response to cytotoxic chemotherapy in colorectal liver metastases (Preprint)
DOI: 10.1101/2021.09.22.459429
382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring (Journal article)
Seligmann, J., Fisher, D. J., Brown, L. C., Adams, R., Graham, J., Quirke, P., . . . Maughan, T. (2021). 382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Annals of Oncology, 32, S530. doi:10.1016/j.annonc.2021.08.904DOI: 10.1016/j.annonc.2021.08.904
430P Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer (Journal article)
Graham, J., Brown, L. C., Adams, R. A., Seligmann, J., Wilson, R., & Maughan, T. (2021). 430P Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer. Annals of Oncology, 32, S549. doi:10.1016/j.annonc.2021.08.951DOI: 10.1016/j.annonc.2021.08.951
431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC) (Journal article)
Adams, R. A., Fisher, D. J., Graham, J., Seligmann, J., Seymour, M., Kaplan, R. S., . . . Maughan, T. (2021). 431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC). Annals of Oncology, 32, S549. doi:10.1016/j.annonc.2021.08.952DOI: 10.1016/j.annonc.2021.08.952
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. (Journal article)
Henderson, R. H., French, D., Maughan, T., Adams, R., Allemani, C., Minicozzi, P., . . . Lawler, M. (2021). The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study.. The lancet. Gastroenterology & hepatology, 6(9), 709-722. doi:10.1016/s2468-1253(21)00147-3DOI: 10.1016/s2468-1253(21)00147-3
Naszai, M., Kurjan, A., & Maughan, T. S. (2021). The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: A systematic review and meta-analysis.. Cancer medicine, 10(17), 5983-5997. doi:10.1002/cam4.4143DOI: 10.1002/cam4.4143
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. (Journal article)
Adams, R., Goey, K., Chibaudel, B., Koopman, M., Punt, C., Arnold, D., . . . Fisher, D. (2021). Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.. Cancer treatment reviews, 99, 102226. doi:10.1016/j.ctrv.2021.102226DOI: 10.1016/j.ctrv.2021.102226
O'Cathail, S. M., Wu, C. -H., Thomas, R., Hawkins, M. A., Maughan, T. S., & Lewis, A. (2021). NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch.. Antioxidants (Basel, Switzerland), 10(9), 1380. doi:10.3390/antiox10091380DOI: 10.3390/antiox10091380
The Molecular Subtyping Resource (MouSR): a user-friendly tool for rapid biological discovery from human or mouse transcriptional data (Preprint)
DOI: 10.1101/2021.08.12.456127
Mukherjee, S., Hurt, C., Radhakrishna, G., Gwynne, S., Bateman, A., Gollins, S., . . . Crosby, T. D. L. (2021). Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial.. European journal of cancer (Oxford, England : 1990), 153, 153-161. doi:10.1016/j.ejca.2021.05.020DOI: 10.1016/j.ejca.2021.05.020
PO-1793 Quantifying the oxygen fixation mechanism in charged particle beams (Journal article)
Van den Heuvel, F., Vella, A., Fiorini, F., Brooke, M., Hill, M., & Maughan, T. (2021). PO-1793 Quantifying the oxygen fixation mechanism in charged particle beams. Radiotherapy and Oncology, 161, S1519. doi:10.1016/s0167-8140(21)08244-xDOI: 10.1016/s0167-8140(21)08244-x
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. (Journal article)
Eyres, M., Lanfredini, S., Xu, H., Burns, A., Blake, A., Willenbrock, F., . . . O'Neill, E. (2021). TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.. Gastroenterology, 161(2), 653-668.e16. doi:10.1053/j.gastro.2021.04.044DOI: 10.1053/j.gastro.2021.04.044
Van den Heuvel, F., Vella, A., Fiorini, F., Brooke, M., Hill, M. A., & Maughan, T. (2021). Incorporating oxygenation levels in analytical DNA-damage models-quantifying the oxygen fixation mechanism.. Physics in medicine and biology, 66(14). doi:10.1088/1361-6560/ac0b80DOI: 10.1088/1361-6560/ac0b80
Leach, J. D. G., Vlahov, N., Tsantoulis, P., Ridgway, R. A., Flanagan, D. J., Gilroy, K., . . . Sansom, O. J. (2021). Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis.. Nature communications, 12(1), 3464. doi:10.1038/s41467-021-23717-5DOI: 10.1038/s41467-021-23717-5
Zhang, P., Kitchen-Smith, I., Xiong, L., Stracquadanio, G., Brown, K., Richter, P. H., . . . Bond, G. L. (2021). Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.. Cancer research, 81(7), 1667-1680. doi:10.1158/0008-5472.can-20-0177DOI: 10.1158/0008-5472.can-20-0177
Culliford, R., Cornish, A. J., Law, P. J., Farrington, S. M., Palin, K., Jenkins, M. A., . . . Houlston, R. S. (2021). Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.. British journal of cancer, 124(6), 1169-1174. doi:10.1038/s41416-020-01211-xDOI: 10.1038/s41416-020-01211-x
Sirinukunwattana, K., Domingo, E., Richman, S. D., Redmond, K. L., Blake, A., Verrill, C., . . . S:CORT consortium. (2021). Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.. Gut, 70(3), 544-554. doi:10.1136/gutjnl-2019-319866DOI: 10.1136/gutjnl-2019-319866
Whalley, C., Payne, K., Domingo, E., Blake, A., Richman, S., Brooks, J., . . . Beggs, A. D. (2021). Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA.. Epigenomes, 5(1), 6. doi:10.3390/epigenomes5010006DOI: 10.3390/epigenomes5010006
The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors. (Journal article)
van Bijsterveldt, L., Durley, S. C., Maughan, T. S., & Humphrey, T. C. (2021). The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors.. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(4), 937-962. doi:10.1158/1078-0432.ccr-20-3358DOI: 10.1158/1078-0432.ccr-20-3358
Willenbrock, F., Cox, C. M., Parkes, E. E., Wilhelm-Benartzi, C. S., Abraham, A. G., Owens, R., . . . Mukherjee, S. (2021). Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.. British journal of cancer, 124(3), 581-586. doi:10.1038/s41416-020-01120-zDOI: 10.1038/s41416-020-01120-z
Yin, J., Dawood, S., Cohen, R., Meyers, J., Zalcberg, J., Yoshino, T., . . . Adams, R. (2021). Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.. Therapeutic advances in medical oncology, 13, 17588359211020547. doi:10.1177/17588359211020547DOI: 10.1177/17588359211020547
Malla, S. B., Fisher, D. J., Domingo, E., Blake, A., Hassanieh, S., Redmond, K. L., . . . S:CORT consortium. (2021). In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(1), 288-300. doi:10.1158/1078-0432.ccr-20-3237DOI: 10.1158/1078-0432.ccr-20-3237
2020
Oxygen Related Factors in FLASH Radiotherapy (Journal article)
Van Den Heuvel, F., Petersson, K., Vojnovic, B., Hill, M., Vella, A., Ryan, A., . . . Giaccia, A. J. (2020). Oxygen Related Factors in FLASH Radiotherapy. International Journal of Radiation Oncology*Biology*Physics, 108(3), e534. doi:10.1016/j.ijrobp.2020.07.1668DOI: 10.1016/j.ijrobp.2020.07.1668
TET2 drives 5hmc marking of <i>GATA6</i> and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes (Preprint)
DOI: 10.1101/2020.10.22.342436
Craig, S. G., Humphries, M. P., Alderdice, M., Bingham, V., Richman, S. D., Loughrey, M. B., . . . Salto-Tellez, M. (2020). Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.. British journal of cancer, 123(8), 1280-1288. doi:10.1038/s41416-020-0985-5DOI: 10.1038/s41416-020-0985-5
Viratham Pulsawatdi, A., Craig, S. G., Bingham, V., McCombe, K., Humphries, M. P., Senevirathne, S., . . . Salto-Tellez, M. (2020). A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.. Molecular oncology, 14(10), 2384-2402. doi:10.1002/1878-0261.12764DOI: 10.1002/1878-0261.12764
Fusobacterium nucleatum, rectal cancer and radiotherapy. (Journal article)
Mann, E. H., & Maughan, T. S. (2020). Fusobacterium nucleatum, rectal cancer and radiotherapy.. Annals of oncology : official journal of the European Society for Medical Oncology, 31(10), 1277-1278. doi:10.1016/j.annonc.2020.06.019DOI: 10.1016/j.annonc.2020.06.019
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. (Journal article)
O'Cathail, S. M., Wu, C. -H., Lewis, A., Holmes, C., Hawkins, M. A., & Maughan, T. (2020). NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.. Cancer genetics, 248-249, 1-10. doi:10.1016/j.cancergen.2020.08.006DOI: 10.1016/j.cancergen.2020.08.006
432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database (Journal article)
Papamichael, D., Lopes, G. S., Olswold, C. L., Chibaudel, B., Zalcberg, J. R., Van Cutsem, E., . . . Shi, Q. (2020). 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database. Annals of Oncology, 31, S425. doi:10.1016/j.annonc.2020.08.543DOI: 10.1016/j.annonc.2020.08.543
Barber, P. R., Weitsman, G., Lawler, K., Barrett, J. E., Rowley, M., Rodriguez-Justo, M., . . . Ng, T. (2020). HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial.. Journal of the National Cancer Institute, 112(9), 944-954. doi:10.1093/jnci/djz231DOI: 10.1093/jnci/djz231
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. (Journal article)
McCuaig, S., Barras, D., Mann, E. H., Friedrich, M., Bullers, S. J., Janney, A., . . . Powrie, F. (2020). The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(16), 4313-4325. doi:10.1158/1078-0432.ccr-19-1086DOI: 10.1158/1078-0432.ccr-19-1086
O'Cathail, S. M., Davis, S., Holmes, J., Brown, R., Fisher, K., Seymour, L., . . . Hawkins, M. A. (2020). A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).. Radiation oncology (London, England), 15(1), 151. doi:10.1186/s13014-020-01593-5DOI: 10.1186/s13014-020-01593-5
Kleeman, S. O., Koelzer, V. H., Jones, H. J., Vazquez, E. G., Davis, H., East, J. E., . . . Leedham, S. J. (2020). Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification.. Gut, 69(6), 1092-1103. doi:10.1136/gutjnl-2019-319126DOI: 10.1136/gutjnl-2019-319126
Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019) (Journal article)
Ren, L., Zhu, D., Benson, A. B. I. I. I., Nordlinger, B., Koehne, C. -H., Delaney, C. P., . . . Xu, J. (2020). Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). EJSO, 46(6), 955-966. doi:10.1016/j.ejso.2020.02.019DOI: 10.1016/j.ejso.2020.02.019
Brown, N. F., Ng, S. M., Brooks, C., Coutts, T., Holmes, J., Roberts, C., . . . Mulholland, P. (2020). A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.. BMC cancer, 20(1), 198. doi:10.1186/s12885-020-6624-yDOI: 10.1186/s12885-020-6624-y
Fielden, J., Wiseman, K., Torrecilla, I., Li, S., Hume, S., Chiang, S. -C., . . . Ramadan, K. (2020). TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts.. Nature communications, 11(1), 1274. doi:10.1038/s41467-020-15000-wDOI: 10.1038/s41467-020-15000-w
Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., . . . New EPOC investigators. (2020). Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.. The Lancet. Oncology, 21(3), 398-411. doi:10.1016/s1470-2045(19)30798-3DOI: 10.1016/s1470-2045(19)30798-3
Jones, D. A., Smith, J., Mei, X. W., Hawkins, M. A., Maughan, T., van den Heuvel, F., . . . Gray, A. (2020). A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality.. Clinical and translational radiation oncology, 20, 19-26. doi:10.1016/j.ctro.2019.10.007DOI: 10.1016/j.ctro.2019.10.007
Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants. (Journal article)
Summers, M. G., Maughan, T. S., Kaplan, R., Law, P. J., Houlston, R. S., Escott-Price, V., & Cheadle, J. P. (2020). Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.. European journal of cancer (Oxford, England : 1990), 124, 56-63. doi:10.1016/j.ejca.2019.09.024DOI: 10.1016/j.ejca.2019.09.024
Cornish, A. J., Law, P. J., Timofeeva, M., Palin, K., Farrington, S. M., Palles, C., . . . Houlston, R. S. (2020). Modifiable pathways for colorectal cancer: a mendelian randomisation analysis.. The lancet. Gastroenterology & hepatology, 5(1), 55-62. doi:10.1016/s2468-1253(19)30294-8DOI: 10.1016/s2468-1253(19)30294-8
2019
Abstract PR02: Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes (Journal article)
Eyres, M., Lanfredini, S., Willenbrock, F., Thapa, A., Blake, A., Burns, A., . . . O'Neill, E. (2019). Abstract PR02: Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes. Cancer Research, 79(24_Supplement), PR02. doi:10.1158/1538-7445.panca19-pr02DOI: 10.1158/1538-7445.panca19-pr02
Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response (Preprint)
DOI: 10.1101/835918
Thomas, R., Trapani, D., Goodyer-Sait, L., Tomkova, M., Fernandez-Rozadilla, C., Sahnane, N., . . . Lewis, A. (2019). The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression.. Scientific reports, 9(1), 13463. doi:10.1038/s41598-019-49952-xDOI: 10.1038/s41598-019-49952-x
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. (Journal article)
Burzykowski, T., Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Bokemeyer, C., . . . Aide et Recherche en Cancerologie Digestive Group. (2019). Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.. JAMA network open, 2(9), e1911750. doi:10.1001/jamanetworkopen.2019.11750DOI: 10.1001/jamanetworkopen.2019.11750
NRF2 Metagene Expression Associated with Worse Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer (Journal article)
O'Cathail, S. M., Chieh, W. H., Maughan, T. S., & Hawkins, M. A. (2019). NRF2 Metagene Expression Associated with Worse Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics, 105(1), S160. doi:10.1016/j.ijrobp.2019.06.177DOI: 10.1016/j.ijrobp.2019.06.177
Gray, V., Briggs, S., Palles, C., Jaeger, E., Iveson, T., Kerr, R., . . . Church, D. N. (2019). Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.. Journal of the National Cancer Institute, 111(8), 828-836. doi:10.1093/jnci/djy215DOI: 10.1093/jnci/djy215
CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial (Journal article)
Willenbrock, F., Cox, C., Wilhelm-benartzic, C., Owens, R., Sabbagh, A., Abraham, A., . . . Mukherjee, S. (2019). CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial. Annals of Oncology, 30, iv110. doi:10.1093/annonc/mdz156.001DOI: 10.1093/annonc/mdz156.001
Hague, D., Townsend, S., Masters, L., Rauchenberger, M., Van Looy, N., Diaz-Montana, C., . . . STAMPEDE and FOCUS4 investigators. (2019). Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.. Trials, 20(1), 294. doi:10.1186/s13063-019-3322-7DOI: 10.1186/s13063-019-3322-7
Morrell, L., Hordern, J., Brown, L., Sydes, M. R., Amos, C. L., Kaplan, R. S., . . . Maughan, T. S. (2019). Mind the gap? The platform trial as a working environment.. Trials, 20(1), 297. doi:10.1186/s13063-019-3377-5DOI: 10.1186/s13063-019-3377-5
Schiavone, F., Bathia, R., Letchemanan, K., Masters, L., Amos, C., Bara, A., . . . past and present members of the STAMPEDE and FOCUS4 Trial Management Group. (2019). This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.. Trials, 20(1), 264. doi:10.1186/s13063-019-3216-8DOI: 10.1186/s13063-019-3216-8
Henderson, R., French, D., Sullivan, R., Maughan, T., Clarke, M., & Lawler, M. (2019). Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.. Oncotarget, 10(36), 3408-3423. doi:10.18632/oncotarget.26909DOI: 10.18632/oncotarget.26909
Association analyses identify 31 new risk loci for colorectal cancer susceptibility (Journal article)
Law, P. J., Timofeeva, M., Fernandez-Rozadilla, C., Timofeeva, A., Broderick, P., Studd, J., . . . Thibodeau, S. N. (2019). Association analyses identify 31 new risk loci for colorectal cancer susceptibility. NATURE COMMUNICATIONS, 10. doi:10.1038/s41467-019-09775-wDOI: 10.1038/s41467-019-09775-w
McGowan, D. R., Skwarski, M., Bradley, K. M., Campo, L., Fenwick, J. D., Gleeson, F. V., . . . Higgins, G. S. (2019). Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma. EUROPEAN JOURNAL OF CANCER, 113, 87-95. doi:10.1016/j.ejca.2019.03.015DOI: 10.1016/j.ejca.2019.03.015
Guidelines for using sigQC for systematic evaluation of gene signatures. (Journal article)
Dhawan, A., Barberis, A., Cheng, W. -C., Domingo, E., West, C., Maughan, T., . . . Buffa, F. M. (2019). Guidelines for using sigQC for systematic evaluation of gene signatures.. Nature protocols, 14(5), 1377-1400. doi:10.1038/s41596-019-0136-8DOI: 10.1038/s41596-019-0136-8
Strauss, V. Y., Shaw, R., Virdee, P. S., Hurt, C. N., Ward, E., Tranter, B., . . . Mukherjee, S. (2019). Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).. BMC cancer, 19(1), 121. doi:10.1186/s12885-019-5307-zDOI: 10.1186/s12885-019-5307-z
2018
Are All Colorectal Oligometastases Equal? (Journal article)
O'Cathail, S. M., Owens, R., Maughan, T. S., & Hawkins, M. A. (2018). Are All Colorectal Oligometastases Equal?. International Journal of Radiation Oncology*Biology*Physics, 102(3), e14. doi:10.1016/j.ijrobp.2018.07.224DOI: 10.1016/j.ijrobp.2018.07.224
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. (Journal article)
Salem, M. E., Yin, J., Weinberg, B. A., Renfro, L. A., Pederson, L. D., Maughan, T. S., . . . Marshall, J. L. (2018). Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.. European journal of cancer (Oxford, England : 1990), 103, 205-213. doi:10.1016/j.ejca.2018.08.020DOI: 10.1016/j.ejca.2018.08.020
KEAP1-NRF2 Pathway as a Modulator of Response to Radiation in Rectal Cancer (Journal article)
O'Cathail, S. M., Lewis, A., Hawkins, M. A., & Maughan, T. S. (2018). KEAP1-NRF2 Pathway as a Modulator of Response to Radiation in Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics, 102(3), e191-e192. doi:10.1016/j.ijrobp.2018.07.693DOI: 10.1016/j.ijrobp.2018.07.693
Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials (Journal article)
Madi, A., Fisher, D., Maughan, T. S., Colley, J. P., Meade, A. M., Maynard, J., . . . Cheadle, J. P. (2018). Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Annals of Oncology, 29, viii22. doi:10.1093/annonc/mdy269.072DOI: 10.1093/annonc/mdy269.072
Kannan, P., Kretzschmar, W. W., Winter, H., Warren, D., Bates, R., Allen, P. D., . . . Kersemans, V. (2018). Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases.. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(19), 4694-4704. doi:10.1158/1078-0432.ccr-18-0033DOI: 10.1158/1078-0432.ccr-18-0033
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy (Journal article)
Madi, A., Fisher, D., Maughan, T. S., Colley, J. P., Meade, A. M., Maynard, J., . . . Cheadle, J. P. (2018). Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. EUROPEAN JOURNAL OF CANCER, 102, 31-39. doi:10.1016/j.ejca.2018.07.009DOI: 10.1016/j.ejca.2018.07.009
SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component (Journal article)
Mukherjee, S., Virdee, P., Shaw, R., Bridgewater, J., Radhakrishna, G., Falk, S., . . . Maughan, T. S. (2018). SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component. Annals of Oncology, 29, viii243. doi:10.1093/annonc/mdy282.103DOI: 10.1093/annonc/mdy282.103
Safety and Tumour Hypoxia Modifying Effect of Buparlisib with Radiotherapy in NSCLC: A Phase I Dose Escalation Study (Conference Paper)
Skwarski, M., Mcgowan, D., Bradley, K., Fenwick, J., Gleeson, F., Horne, A., . . . Higgins, G. (2018). Safety and Tumour Hypoxia Modifying Effect of Buparlisib with Radiotherapy in NSCLC: A Phase I Dose Escalation Study. In JOURNAL OF THORACIC ONCOLOGY Vol. 13 (pp. S594). doi:10.1016/j.jtho.2018.08.888DOI: 10.1016/j.jtho.2018.08.888
Cross, W., Kovac, M., Mustonen, V., Temko, D., Davis, H., Baker, A. -M., . . . Tomlinson, I. P. M. (2018). The evolutionary landscape of colorectal tumorigenesis.. Nature ecology & evolution, 2(10), 1661-1672. doi:10.1038/s41559-018-0642-zDOI: 10.1038/s41559-018-0642-z
Gollins, S., West, N., Sebag-Montefiore, D., Susnerwala, S., Falk, S., Brown, N., . . . Hurt, C. (2018). A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.. British journal of cancer, 119(6), 697-706. doi:10.1038/s41416-018-0209-4DOI: 10.1038/s41416-018-0209-4
Abstract 5175: Advancing the molecular understanding of stage I colorectal cancer (Journal article)
Dunne, P., Loughrey, M. B., Coleman, H. G., McBride, R., Campbell, J., Alderdice, M., . . . consortium, S. C. (2018). Abstract 5175: Advancing the molecular understanding of stage I colorectal cancer. Cancer Research, 78(13_Supplement), 5175. doi:10.1158/1538-7445.am2018-5175DOI: 10.1158/1538-7445.am2018-5175
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies (Conference Paper)
Alderdice, M., Richman, S. D., Gollins, S., Stewart, P., Hurt, C., Adams, R., . . . Dunne, P. D. (2018). Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-5365DOI: 10.1158/1538-7445.AM2018-5365
Sjoquist, K. M., Renfro, L. A., Simes, R. J., Tebbutt, N. C., Clarke, S., Seymour, M. T., . . . Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD). (2018). Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.. Journal of the National Cancer Institute, 110(6), 638-648. doi:10.1093/jnci/djx253DOI: 10.1093/jnci/djx253
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies (Journal article)
Alderdice, M., Richman, S. D., Gollins, S., Stewart, J. P., Hurt, C., Adams, R., . . . Dunne, P. D. (2018). Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. JOURNAL OF PATHOLOGY, 245(1), 19-28. doi:10.1002/path.5051DOI: 10.1002/path.5051
Sobrero, A., Grothey, A., Iveson, T., Labianca, R., Yoshino, T., Taieb, J., . . . Cervantes, A. (2018). The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Annals of oncology : official journal of the European Society for Medical Oncology, 29(5), 1099-1107. doi:10.1093/annonc/mdy064DOI: 10.1093/annonc/mdy064
Adams, R., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., . . . FOCUS4 Trial Investigators. (2018). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.. The lancet. Gastroenterology & hepatology, 3(3), 162-171. doi:10.1016/s2468-1253(17)30394-1DOI: 10.1016/s2468-1253(17)30394-1
Tanskanen, T., van den Berg, L., Välimäki, N., Aavikko, M., Ness-Jensen, E., Hveem, K., . . . Aaltonen, L. A. (2018). Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.. International journal of cancer, 142(3), 540-546. doi:10.1002/ijc.31076DOI: 10.1002/ijc.31076
Advanced Radiotherapy Technologies Network in the UK (ART-NET) – focus on lung cancer (Journal article)
Brown, S., Van Herk, M., Chuter, R., Falk, S., Kirkby, K., Mackay, R., . . . Faivre-Finn, C. (2018). Advanced Radiotherapy Technologies Network in the UK (ART-NET) – focus on lung cancer. Lung Cancer, 115, S60. doi:10.1016/s0169-5002(18)30166-1DOI: 10.1016/s0169-5002(18)30166-1
Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy. (Journal article)
West, H., Coffey, M., Wagner, M. J., McLeod, H. L., Colley, J. P., Adams, R. A., . . . Cheadle, J. P. (2018). Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy.. JCO precision oncology, 2, 1-18. doi:10.1200/po.18.00090DOI: 10.1200/po.18.00090
2017
Harrington, K., Hall, E., Hawkins, M., Henry, A., MacKay, R., Maughan, T., . . . ART-NET Steering Committee. (2017). Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).. Clinical oncology (Royal College of Radiologists (Great Britain)), 29(11), 707-710. doi:10.1016/j.clon.2017.07.016DOI: 10.1016/j.clon.2017.07.016
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis (Journal article)
May-Wilson, S., Sud, A., Law, P. J., Palin, K., Tuupanen, S., Gylfe, A., . . . Houlston, R. S. (2017). Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. EUROPEAN JOURNAL OF CANCER, 84, 228-238. doi:10.1016/j.ejca.2017.07.034DOI: 10.1016/j.ejca.2017.07.034
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. (Conference Paper)
Parmar, M. K., Sydes, M. R., Cafferty, F. H., Choodari-Oskooei, B., Langley, R. E., Brown, L., . . . Royston, P. J. (2017). Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.. In Clinical trials (London, England) Vol. 14 (pp. 451-461). doi:10.1177/1740774517725697DOI: 10.1177/1740774517725697
Puri, T., Greenhalgh, T. A., Wilson, J. M., Franklin, J., Wang, L. M., Strauss, V., . . . Maughan, T. (2017). [<sup>18</sup>F]Fluoromisonidazole PET in rectal cancer.. EJNMMI research, 7(1), 78. doi:10.1186/s13550-017-0324-xDOI: 10.1186/s13550-017-0324-x
How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. (Journal article)
Bonnetain, F., Borg, C., Adams, R. R., Ajani, J. A., Benson, A., Bleiberg, H., . . . de Gramont, A. (2017). How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.. Annals of oncology : official journal of the European Society for Medical Oncology, 28(9), 2077-2085. doi:10.1093/annonc/mdx191DOI: 10.1093/annonc/mdx191
Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial (Journal article)
Bridgewater, J., Pugh, S., Whitehead, A., Stanton, L., Eminton, Z., Mellor, J., . . . Primrose, J. (2017). Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial. Annals of Oncology, 28, v162. doi:10.1093/annonc/mdx393.010DOI: 10.1093/annonc/mdx393.010
Surgical quality and the impact of liver resection on outcome in the new EPOC study (Journal article)
Pugh, S., Bridgewater, J., Finch-Jones, M., Rees, M., O'Reilly, D., Peterson, M., . . . Primrose, J. (2017). Surgical quality and the impact of liver resection on outcome in the new EPOC study. Annals of Oncology, 28, v167-v168. doi:10.1093/annonc/mdx393.020DOI: 10.1093/annonc/mdx393.020
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. (Journal article)
Madi, A., Fisher, D., Maughan, T. S., Colley, J. P., Meade, A. M., Tejpar, S., . . . Cheadle, J. P. (2017). Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.. Journal of medical genetics, 54(8), 567-571. doi:10.1136/jmedgenet-2016-104317DOI: 10.1136/jmedgenet-2016-104317
Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables. (Journal article)
Stewart, J. P., Richman, S., Maughan, T., Lawler, M., Dunne, P. D., & Salto-Tellez, M. (2017). Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables.. Biochimica et biophysica acta. Reviews on cancer, 1868(1), 258-272. doi:10.1016/j.bbcan.2017.05.005DOI: 10.1016/j.bbcan.2017.05.005
O'Cathail, S. M., Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W., & Hawkins, M. A. (2017). Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.. Frontiers in oncology, 7, 153. doi:10.3389/fonc.2017.00153DOI: 10.3389/fonc.2017.00153
Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer (Journal article)
Rodriguez-Broadbent, H., Law, P. J., Sud, A., Palin, K., Tuupanen, S., Gylfe, A., . . . Houlston, R. S. (2017). Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, 140(12), 2701-2708. doi:10.1002/ijc.30709DOI: 10.1002/ijc.30709
Prevo, R., Tiwana, G. S., Maughan, T. S., Buffa, F. M., McKenna, W. G., & Higgins, G. S. (2017). Depletion of signal recognition particle 72kDa increases radiosensitivity.. Cancer biology & therapy, 18(6), 425-432. doi:10.1080/15384047.2017.1323587DOI: 10.1080/15384047.2017.1323587
<i>BRAF</i> and <i>NRAS</i> Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. (Journal article)
Summers, M. G., Smith, C. G., Maughan, T. S., Kaplan, R., Escott-Price, V., & Cheadle, J. P. (2017). <i>BRAF</i> and <i>NRAS</i> Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(11), 2742-2749. doi:10.1158/1078-0432.ccr-16-1541DOI: 10.1158/1078-0432.ccr-16-1541
Dunne, P. D., Alderdice, M., O'Reilly, P. G., Roddy, A. C., McCorry, A. M. B., Richman, S., . . . Lawler, M. (2017). Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification.. Nature communications, 8, 15657. doi:10.1038/ncomms15657DOI: 10.1038/ncomms15657
Hurt, C. N., Falk, S., Crosby, T., McDonald, A., Ray, R., Joseph, G., . . . Mukherjee, S. (2017). Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.. British journal of cancer, 116(10), 1264-1270. doi:10.1038/bjc.2017.95DOI: 10.1038/bjc.2017.95
EP-1278: FMISO-PET & perfusion CT at baseline and; week 2 CRT as predictive markers for response in rectal ca (Journal article)
Greenhalgh, T., Wilson, J., Puri, T., Franklin, J., Wang, L., Goldin, R., . . . Maughan, T. (2017). EP-1278: FMISO-PET & perfusion CT at baseline and; week 2 CRT as predictive markers for response in rectal ca. Radiotherapy and Oncology, 123, S686-S687. doi:10.1016/s0167-8140(17)31713-9DOI: 10.1016/s0167-8140(17)31713-9
Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Staffurth, J., Ray, R., . . . Mukherjee, S. (2017). Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.. British journal of cancer, 116(6), 709-716. doi:10.1038/bjc.2017.21DOI: 10.1038/bjc.2017.21
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. (Journal article)
Wood, G., Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., . . . Bridgewater, J. (2017). Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.. Anti-cancer drugs, 28(5), 546-550. doi:10.1097/cad.0000000000000488DOI: 10.1097/cad.0000000000000488
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. (Journal article)
Seligmann, J. F., Fisher, D., Smith, C. G., Richman, S. D., Elliott, F., Brown, S., . . . Middleton, G. (2017). Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.. Annals of oncology : official journal of the European Society for Medical Oncology, 28(3), 562-568. doi:10.1093/annonc/mdw645DOI: 10.1093/annonc/mdw645
Mukherjee, S., Hurt, C. N., Gwynne, S., Sebag-Montefiore, D., Radhakrishna, G., Gollins, S., . . . Crosby, T. (2017). NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.. European journal of cancer (Oxford, England : 1990), 74, 38-46. doi:10.1016/j.ejca.2016.11.031DOI: 10.1016/j.ejca.2016.11.031
Lawler, M., & Maughan, T. (2017). From Rosalind Franklin to Barack Obama: Data Sharing Challenges and Solutions in Genomics and Personalised Medicine.. The New bioethics : a multidisciplinary journal of biotechnology and the body, 23(1), 64-73. doi:10.1080/20502877.2017.1314883DOI: 10.1080/20502877.2017.1314883
Personalised Medicine: The Promise, the Hype and the Pitfalls. (Journal article)
Feiler, T., Gaitskell, K., Maughan, T., & Hordern, J. (2017). Personalised Medicine: The Promise, the Hype and the Pitfalls.. The New bioethics : a multidisciplinary journal of biotechnology and the body, 23(1), 1-12. doi:10.1080/20502877.2017.1314895DOI: 10.1080/20502877.2017.1314895
Maughan, T. (2017). The Promise and the Hype of 'Personalised Medicine'.. The New bioethics : a multidisciplinary journal of biotechnology and the body, 23(1), 13-20. doi:10.1080/20502877.2017.1314886DOI: 10.1080/20502877.2017.1314886
2016
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. (Journal article)
Franko, J., Shi, Q., Meyers, J. P., Maughan, T. S., Adams, R. A., Seymour, M. T., . . . Analysis and Research in Cancers of the Digestive System (ARCAD) Group. (2016). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.. The Lancet. Oncology, 17(12), 1709-1719. doi:10.1016/s1470-2045(16)30500-9DOI: 10.1016/s1470-2045(16)30500-9
Leszczynska, K. B., Dobrynin, G., Leslie, R. E., Ient, J., Boumelha, A. J., Senra, J. M., . . . Hammond, E. M. (2016). Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 121(2), 232-238. doi:10.1016/j.radonc.2016.10.023DOI: 10.1016/j.radonc.2016.10.023
FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS (Journal article)
Adams, R. A., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., . . . Maughan, T. (2016). FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. Annals of Oncology, 27, vi168. doi:10.1093/annonc/mdw370.57DOI: 10.1093/annonc/mdw370.57
MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours (Journal article)
Wilson, R., Middleton, M. R., Houlden, J., Van Schaeybroeck, S., Rolfo, C. D., Elez, E., . . . Di Nicolantonio, F. (2016). MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. Annals of Oncology, 27, vi158. doi:10.1093/annonc/mdw370.28DOI: 10.1093/annonc/mdw370.28
Weber, A. M., Drobnitzky, N., Devery, A. M., Bokobza, S. M., Adams, R. A., Maughan, T. S., & Ryan, A. J. (2016). Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.. Oncotarget, 7(38), 60807-60822. doi:10.18632/oncotarget.11845DOI: 10.18632/oncotarget.11845
Pugh, S. A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J. W., . . . Primrose, J. N. (2016). Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.. British journal of cancer, 115(4), 420-424. doi:10.1038/bjc.2016.208DOI: 10.1038/bjc.2016.208
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (Journal article)
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., . . . Arnold, D. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 27(8), 1386-1422. doi:10.1093/annonc/mdw235DOI: 10.1093/annonc/mdw235
Jarvis, D., Mitchell, J. S., Law, P. J., Palin, K., Tuupanen, S., Gylfe, A., . . . Houlston, R. S. (2016). Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.. British journal of cancer, 115(2), 266-272. doi:10.1038/bjc.2016.188DOI: 10.1038/bjc.2016.188
O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC) (Journal article)
Hurt, C., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., Crosby, T., . . . Mukherjee, S. (2016). O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Annals of Oncology, 27, ii118. doi:10.1093/annonc/mdw198.03DOI: 10.1093/annonc/mdw198.03
Powering the Smart City (Journal article)
Maughan, T. (2016). Powering the Smart City. Engineering & Technology, 11(5), 26-29. doi:10.1049/et.2016.0500DOI: 10.1049/et.2016.0500
SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (± nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer (Journal article)
Mukherjee, S., Virdee, P., Love, S., Ward, E., Hamill, C., Hurt, C. N., . . . Bridgewater, J. (2016). SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (± nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer. Pancreatology, 16(3), S3-S4. doi:10.1016/j.pan.2016.04.016DOI: 10.1016/j.pan.2016.04.016
Orlando, G., Law, P. J., Palin, K., Tuupanen, S., Gylfe, A., Hänninen, U. A., . . . Houlston, R. S. (2016). Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.. Human molecular genetics, 25(11), 2349-2359. doi:10.1093/hmg/ddw087DOI: 10.1093/hmg/ddw087
WE‐AB‐202‐10: Modelling Individual Tumor‐Specific Control Probability for Hypoxia in Rectal Cancer (Journal article)
Warren, S., Warren, D. R., Wilson, J. M., Muirhead, R., Hawkins, M. A., Maughan, T., & Partridge, M. (2016). WE‐AB‐202‐10: Modelling Individual Tumor‐Specific Control Probability for Hypoxia in Rectal Cancer. Medical Physics, 43(6Part38), 3796. doi:10.1118/1.4957751DOI: 10.1118/1.4957751
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer (Journal article)
Wilson, J. M., Fokas, E., Dutton, S. J., Patel, N., Hawkins, M. A., Eccles, C., . . . Brunner, T. B. (2016). ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. RADIOTHERAPY AND ONCOLOGY, 119(2), 306-311. doi:10.1016/j.radonc.2016.03.021DOI: 10.1016/j.radonc.2016.03.021
Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T., & Bridgewater, J. (2016). Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.. British journal of cancer, 114(6), 612-615. doi:10.1038/bjc.2016.23DOI: 10.1038/bjc.2016.23
Graham, J. S., Boyd, K., Coxon, F. Y., Wall, L. R., Eatock, M. M., Maughan, T. S., . . . Evans, T. R. J. (2016). A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.. BMC research notes, 9, 161. doi:10.1186/s13104-015-1778-4DOI: 10.1186/s13104-015-1778-4
Molecular Taxonomy and Tumourigenesis of Colorectal Cancer. (Journal article)
Biswas, S., Holyoake, D., & Maughan, T. S. (2016). Molecular Taxonomy and Tumourigenesis of Colorectal Cancer.. Clinical oncology (Royal College of Radiologists (Great Britain)), 28(2), 73-82. doi:10.1016/j.clon.2015.11.001DOI: 10.1016/j.clon.2015.11.001
Phipps, A. I., Passarelli, M. N., Chan, A. T., Harrison, T. A., Jeon, J., Hutter, C. M., . . . Newcomb, P. A. (2016). Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.. Carcinogenesis, 37(1), 87-95. doi:10.1093/carcin/bgv161DOI: 10.1093/carcin/bgv161
Richman, S. D., Adams, R., Quirke, P., Butler, R., Hemmings, G., Chambers, P., . . . FOCUS4 Trial Management Group. (2016). Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.. Journal of clinical pathology, 69(1), 35-41. doi:10.1136/jclinpath-2015-203097DOI: 10.1136/jclinpath-2015-203097
2015
Is farming the future of cities? (Journal article)
EdwardsMaughan, C. (2015). Is farming the future of cities?. Engineering & Technology, 10(12), 56-59. doi:10.1049/et.2016.1206DOI: 10.1049/et.2016.1206
Hurt, C. N., Mukherjee, S., Bridgewater, J., Falk, S., Crosby, T., McDonald, A., . . . Johnson, C. (2015). Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.. International journal of radiation oncology, biology, physics, 93(4), 810-818. doi:10.1016/j.ijrobp.2015.08.026DOI: 10.1016/j.ijrobp.2015.08.026
2104 Derived neutrophil to lymphocyte ratio is not predictive for use of a continuous or intermittent first-line oxaliplatin/fluoropyrimidine combination in patients with advanced colorectal cancer: A post-hoc analysis of the MRC COIN study (Journal article)
Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T., & Bridgewater, J. (2015). 2104 Derived neutrophil to lymphocyte ratio is not predictive for use of a continuous or intermittent first-line oxaliplatin/fluoropyrimidine combination in patients with advanced colorectal cancer: A post-hoc analysis of the MRC COIN study. European Journal of Cancer, 51, S363-S364. doi:10.1016/s0959-8049(16)31026-7DOI: 10.1016/s0959-8049(16)31026-7
Rees, J., Hurt, C. N., Gollins, S., Mukherjee, S., Maughan, T., Falk, S. J., . . . Crosby, T. (2015). Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.. British journal of cancer, 113(4), 603-610. doi:10.1038/bjc.2015.258DOI: 10.1038/bjc.2015.258
Al-Tassan, N. A., Whiffin, N., Hosking, F. J., Palles, C., Farrington, S. M., Dobbins, S. E., . . . Houlston, R. S. (2015). Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.. Scientific reports, 5, 12372. doi:10.1038/srep12372DOI: 10.1038/srep12372
Smith, C. G., Fisher, D., Harris, R., Maughan, T. S., Phipps, A. I., Richman, S., . . . Cheadle, J. P. (2015). Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(15), 3453-3461. doi:10.1158/1078-0432.ccr-14-3136DOI: 10.1158/1078-0432.ccr-14-3136
Lawler, M., Kaplan, R., Wilson, R. H., Maughan, T., & S-CORT Consortium. (2015). Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.. The oncologist, 20(8), 849-851. doi:10.1634/theoncologist.2015-0014DOI: 10.1634/theoncologist.2015-0014
Is China's hydroelectric revolution green enough? (Journal article)
Maughan, T. (2015). Is China's hydroelectric revolution green enough?. Engineering & Technology, 10(7), 72-75. doi:10.1049/et.2015.0723DOI: 10.1049/et.2015.0723
Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. (Journal article)
Primrose, J. N., Cunningham, D., Garden, O. J., Maughan, T. S., Pugh, S. A., Stanton, L., . . . Bridgewater, J. A. (2015). Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(21), 2405-2406. doi:10.1200/jco.2014.60.1344DOI: 10.1200/jco.2014.60.1344
P-182 Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer – functional imaging is prognostic and provides proof of mechanism (Journal article)
Wilson, J., Hackett, S., Durrant, L., Dutton, S., Chu, K. -Y., Eccles, C., . . . Mukherjee, S. (2015). P-182 Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer – functional imaging is prognostic and provides proof of mechanism. Annals of Oncology, 26, iv53. doi:10.1093/annonc/mdv233.182DOI: 10.1093/annonc/mdv233.182
Al-Tassan, N. A., Whiffin, N., Hosking, F. J., Palles, C., Farrington, S. M., Dobbins, S. E., . . . Houlston, R. S. (2015). A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.. Scientific reports, 5, 10442. doi:10.1038/srep10442DOI: 10.1038/srep10442
ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–Mechanism and clinical outcomes. (Journal article)
Wilson, J. M., Dutton, S. J., Hackett, S. L., Durrant, L., Chu, K. -Y., Eccles, C., . . . Mukherjee, S. (2015). ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–Mechanism and clinical outcomes.. Journal of Clinical Oncology, 33(15_suppl), e15279. doi:10.1200/jco.2015.33.15_suppl.e15279DOI: 10.1200/jco.2015.33.15_suppl.e15279
Mukherjee, S., Hurt, C. N., Gwynne, S., Bateman, A., Gollins, S., Radhakrishna, G., . . . Crosby, T. (2015). NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.. BMC cancer, 15, 48. doi:10.1186/s12885-015-1062-yDOI: 10.1186/s12885-015-1062-y
Correlating Tumour Histology and ex vivo MRI Using Dense Modality-Independent Patch-Based Descriptors (Conference Paper)
Hallack, A., Papież, B. W., Wilson, J., Wang, L. M., Maughan, T., Gooding, M. J., & Schnabel, J. A. (2015). Correlating Tumour Histology and ex vivo MRI Using Dense Modality-Independent Patch-Based Descriptors. In Unknown Conference (pp. 137-145). Springer International Publishing. doi:10.1007/978-3-319-28194-0_17DOI: 10.1007/978-3-319-28194-0_17
2014
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., . . . Koopman, M. (2014). Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(20), 5322-5330. doi:10.1158/1078-0432.ccr-14-0332DOI: 10.1158/1078-0432.ccr-14-0332
Lieu, C. H., Renfro, L. A., de Gramont, A., Meyers, J. P., Maughan, T. S., Seymour, M. T., . . . Aide et Recherche en Cancérologie Digestive Foundation. (2014). Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(27), 2975-2984. doi:10.1200/jco.2013.54.9329DOI: 10.1200/jco.2013.54.9329
Analysis of Progression Free Survival in the New Epoc Study in an All Ras Wild-Type Population (Journal article)
Bridgewater, J. A., Pugh, S. A., Moutasim, K., Thomas, G. J., Thiébaut, R., Liebaert, F., . . . Primrose, J. N. (2014). Analysis of Progression Free Survival in the New Epoc Study in an All Ras Wild-Type Population. Annals of Oncology, 25, iv185. doi:10.1093/annonc/mdu333.44DOI: 10.1093/annonc/mdu333.44
Maughan, T. S., Meade, A. M., Adams, R. A., Richman, S. D., Butler, R., Fisher, D., . . . Kaplan, R. (2014). A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?. British journal of cancer, 110(9), 2178-2186. doi:10.1038/bjc.2014.182DOI: 10.1038/bjc.2014.182
Response. (Journal article)
Smith, C. G., West, H., Harris, R., Idziaszczyk, S., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2014). Response.. Journal of the National Cancer Institute, 106(5), dju087. doi:10.1093/jnci/dju087DOI: 10.1093/jnci/dju087
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. (Journal article)
Becerra, C. R., Salazar, R., Garcia-Carbonero, R., Thomas, A. L., Vázquez-Mazón, F. J., Cassidy, J., . . . Bergsland, E. K. (2014). Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.. Cancer chemotherapy and pharmacology, 73(4), 695-702. doi:10.1007/s00280-014-2391-2DOI: 10.1007/s00280-014-2391-2
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. (Journal article)
Wasan, H., Meade, A. M., Adams, R., Wilson, R., Pugh, C., Fisher, D., . . . COIN-B investigators. (2014). Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.. The Lancet. Oncology, 15(6), 631-639. doi:10.1016/s1470-2045(14)70106-8DOI: 10.1016/s1470-2045(14)70106-8
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. (Journal article)
Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., . . . Bridgewater, J. (2014). Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.. The Lancet. Oncology, 15(6), 601-611. doi:10.1016/s1470-2045(14)70105-6DOI: 10.1016/s1470-2045(14)70105-6
2013
Evaluating many treatments and biomarkers in oncology: a new design. (Journal article)
Kaplan, R., Maughan, T., Crook, A., Fisher, D., Wilson, R., Brown, L., & Parmar, M. (2013). Evaluating many treatments and biomarkers in oncology: a new design.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(36), 4562-4568. doi:10.1200/jco.2013.50.7905DOI: 10.1200/jco.2013.50.7905
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). (Journal article)
Middleton, G., Brown, S., Lowe, C., Maughan, T., Gwyther, S., Oliver, A., . . . Seymour, M. (2013). A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).. European journal of cancer (Oxford, England : 1990), 49(16), 3507-3516. doi:10.1016/j.ejca.2013.06.017DOI: 10.1016/j.ejca.2013.06.017
Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. (Journal article)
Smith, C. G., West, H., Harris, R., Idziaszczyk, S., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2013). Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.. Journal of the National Cancer Institute, 105(16), 1249-1253. doi:10.1093/jnci/djt183DOI: 10.1093/jnci/djt183
Smith, C. G., Fisher, D., Claes, B., Maughan, T. S., Idziaszczyk, S., Peuteman, G., . . . Cheadle, J. P. (2013). Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(15), 4104-4113. doi:10.1158/1078-0432.ccr-12-2581DOI: 10.1158/1078-0432.ccr-12-2581
Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. (Journal article)
Smith, C. G., Naven, M., Harris, R., Colley, J., West, H., Li, N., . . . Cheadle, J. P. (2013). Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.. Human mutation, 34(7), 1026-1034. doi:10.1002/humu.22333DOI: 10.1002/humu.22333
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. (Journal article)
Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., . . . Quirke, P. (2013). Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.. The Lancet. Oncology, 14(8), 749-759. doi:10.1016/s1470-2045(13)70163-3DOI: 10.1016/s1470-2045(13)70163-3
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. (Journal article)
Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., . . . Griffiths, G. (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.. The Lancet. Oncology, 14(7), 627-637. doi:10.1016/s1470-2045(13)70136-0DOI: 10.1016/s1470-2045(13)70136-0
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. (Journal article)
James, R. D., Glynne-Jones, R., Meadows, H. M., Cunningham, D., Myint, A. S., Saunders, M. P., . . . Sebag-Montefiore, D. (2013). Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.. The Lancet. Oncology, 14(6), 516-524. doi:10.1016/s1470-2045(13)70086-xDOI: 10.1016/s1470-2045(13)70086-x
Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. (Journal article)
Powell, J. R., Dojcinov, S., King, L., Wosniak, S., Gerry, S., Casbard, A., . . . Maughan, T. (2013). Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.. Leukemia & lymphoma, 54(5), 959-966. doi:10.3109/10428194.2012.733875DOI: 10.3109/10428194.2012.733875
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. (Journal article)
Mukherjee, S., Hurt, C. N., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., . . . Maughan, T. (2013). Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.. The Lancet. Oncology, 14(4), 317-326. doi:10.1016/s1470-2045(13)70021-4DOI: 10.1016/s1470-2045(13)70021-4
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. (Journal article)
Türbachova, I., Schwachula, T., Vasconcelos, I., Mustea, A., Baldinger, T., Jones, K. A., . . . Olek, S. (2013). The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.. Epigenetics, 8(11), 1226-1235. doi:10.4161/epi.26334DOI: 10.4161/epi.26334
2012
Methodological considerations in the evaluation of radiotherapy technologies. (Journal article)
Burnet, N. G., Billingham, L. J., Chan, C. S. K., Hall, E., Macdougall, J., Mackay, R. I., . . . National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Executive Group. (2012). Methodological considerations in the evaluation of radiotherapy technologies.. Clinical oncology (Royal College of Radiologists (Great Britain)), 24(10), 707-709. doi:10.1016/j.clon.2012.06.003DOI: 10.1016/j.clon.2012.06.003
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. (Journal article)
Vale, C. L., Tierney, J. F., Fisher, D., Adams, R. A., Kaplan, R., Maughan, T. S., . . . Meade, A. M. (2012). Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.. Cancer treatment reviews, 38(6), 618-625. doi:10.1016/j.ctrv.2011.11.002DOI: 10.1016/j.ctrv.2011.11.002
Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now. (Journal article)
MacGregor, T. P., Maughan, T. S., & Sharma, R. A. (2012). Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.. Journal of clinical pathology, 65(10), 867-871. doi:10.1136/jclinpath-2012-200958DOI: 10.1136/jclinpath-2012-200958
Madi, A., Fisher, D., Wilson, R. H., Adams, R. A., Meade, A. M., Kenny, S. L., . . . COIN trial research group. (2012). Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.. British journal of cancer, 107(7), 1037-1043. doi:10.1038/bjc.2012.384DOI: 10.1038/bjc.2012.384
Deficient Mismatch Repair (DMMR) and Braf Mutation (MT) Status in Patients (PTS) With Metastatic Colorectal Cancer (MCRC): A Meta-Analysis of the Cairo, CAIRO2, Coin and Focus Studies (Journal article)
Venderbosch, S., De Haan, T., Heideman, D. A. M., Maughan, T. S., Smith, C. G., Quirke, P., . . . Koopman, M. (2012). Deficient Mismatch Repair (DMMR) and Braf Mutation (MT) Status in Patients (PTS) With Metastatic Colorectal Cancer (MCRC): A Meta-Analysis of the Cairo, CAIRO2, Coin and Focus Studies. Annals of Oncology, 23, ix179. doi:10.1016/s0923-7534(20)33156-2DOI: 10.1016/s0923-7534(20)33156-2
SP-28: Nelfinavir and RT in Pancreatic Cancer (Journal article)
Brunner, T. B., Hill, E., Wilson, J., Maughan, T., Eccles, C., & McKenna, W. G. (2012). SP-28: Nelfinavir and RT in Pancreatic Cancer. Radiotherapy and Oncology, 104, 29. doi:10.1016/s0167-8140(15)34582-5DOI: 10.1016/s0167-8140(15)34582-5
Common variation near <i>CDKN1A</i>, <i>POLD3</i> and <i>SHROOM2</i> influences colorectal cancer risk (Journal article)
Dunlop, M. G., Dobbins, S. E., Farrington, S. M., Jones, A. M., Palles, C., Whiffin, N., . . . Houlston, R. S. (2012). Common variation near <i>CDKN1A</i>, <i>POLD3</i> and <i>SHROOM2</i> influences colorectal cancer risk. NATURE GENETICS, 44(7), 770-U197. doi:10.1038/ng.2293DOI: 10.1038/ng.2293
X-ACT: an important step on an unfinished journey. (Journal article)
Maughan, T. (2012). X-ACT: an important step on an unfinished journey.. Annals of oncology : official journal of the European Society for Medical Oncology, 23(7), 1655-1658. doi:10.1093/annonc/mds114DOI: 10.1093/annonc/mds114
2011
6006 ORAL Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial (Journal article)
Wasan, H., Adams, R. A., Wilson, R. H., Pugh, C. A., Fisher, D., Madi, A., . . . Maughan, T. S. (2011). 6006 ORAL Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial. European Journal of Cancer, 47, S393. doi:10.1016/s0959-8049(11)71651-3DOI: 10.1016/s0959-8049(11)71651-3
6007 ORAL Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification (Journal article)
Seymour, M. T., Brown, S. R., Richman, S., Middleton, G. W., Maughan, T. S., Maisey, N., . . . Quirke, P. (2011). 6007 ORAL Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. European Journal of Cancer, 47, S393. doi:10.1016/s0959-8049(11)71652-5DOI: 10.1016/s0959-8049(11)71652-5
6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification (Journal article)
Middleton, G. W., Brown, S. R., Gwyther, S. J., Maughan, T. S., Wadsley, J., Chau, I., . . . Seymour, M. T. (2011). 6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. European Journal of Cancer, 47, S420-S421. doi:10.1016/s0959-8049(11)71742-7DOI: 10.1016/s0959-8049(11)71742-7
The treatment of patients with low tumour burden and/or slow growing disease. (Journal article)
Maughan, T. S. (2011). The treatment of patients with low tumour burden and/or slow growing disease.. European journal of cancer (Oxford, England : 1990), 47 Suppl 3, S67-S75. doi:10.1016/s0959-8049(11)70149-6DOI: 10.1016/s0959-8049(11)70149-6
Shaw, P. H. S., Maughan, T. S., & Clarke, A. R. (2011). Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.. British journal of cancer, 105(5), 649-657. doi:10.1038/bjc.2011.291DOI: 10.1038/bjc.2011.291
Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., . . . Illidge, T. (2011). Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.. British journal of cancer, 105(5), 628-639. doi:10.1038/bjc.2011.240DOI: 10.1038/bjc.2011.240
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. (Journal article)
Adams, R. A., Meade, A. M., Seymour, M. T., Wilson, R. H., Madi, A., Fisher, D., . . . MRC COIN Trial Investigators. (2011). Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.. The Lancet. Oncology, 12(7), 642-653. doi:10.1016/s1470-2045(11)70102-4DOI: 10.1016/s1470-2045(11)70102-4
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. (Journal article)
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., . . . MRC COIN Trial Investigators. (2011). Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.. Lancet (London, England), 377(9783), 2103-2114. doi:10.1016/s0140-6736(11)60613-2DOI: 10.1016/s0140-6736(11)60613-2
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. (Journal article)
Seymour, M. T., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, S. F., . . . National Cancer Research Institute Colorectal Cancer Clinical Studies Group. (2011). Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.. Lancet (London, England), 377(9779), 1749-1759. doi:10.1016/s0140-6736(11)60399-1DOI: 10.1016/s0140-6736(11)60399-1
A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy. (Journal article)
Thomas, A. L., Wilson, R. H., Steward, W. P., Adams, R. A., Bridges, S. E., Casbard, A. C., . . . Griffiths, G. (2011). A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy.. Journal of Clinical Oncology, 29(15_suppl), TPS161. doi:10.1200/jco.2011.29.15_suppl.tps161DOI: 10.1200/jco.2011.29.15_suppl.tps161
Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). (Journal article)
Seymour, M. T., Brown, S. R., Richman, S., Middleton, G. W., Maughan, T., Olivier, C., . . . Quirke, P. (2011). Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 29(15_suppl), 3523. doi:10.1200/jco.2011.29.15_suppl.3523DOI: 10.1200/jco.2011.29.15_suppl.3523
Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). (Journal article)
Middleton, G. W., Gwyther, S. J., Brown, S. R., Maughan, T., Olivier, C., Richman, S., . . . Seymour, M. T. (2011). Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 29(15_suppl), 3566. doi:10.1200/jco.2011.29.15_suppl.3566DOI: 10.1200/jco.2011.29.15_suppl.3566
Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study. (Journal article)
Maughan, T., Wilson, R. H., Williams, G. T., Seymour, M. T., Richman, S., Quirke, P., . . . Kaplan, R. S. (2011). Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study.. Journal of Clinical Oncology, 29(15_suppl), TPS165. doi:10.1200/jco.2011.29.15_suppl.tps165DOI: 10.1200/jco.2011.29.15_suppl.tps165
Multiplexed quantitation of growth factor receptors and pathway activation in FFPE tumor tissue from the COIN trial. (Journal article)
Adams, R., Hembrough, T. A., Thyparambil, S., Krizman, D., Darfler, M., Jasani, B., . . . Burrows, J. (2011). Multiplexed quantitation of growth factor receptors and pathway activation in FFPE tumor tissue from the COIN trial.. Journal of Clinical Oncology, 29(15_suppl), e14117. doi:10.1200/jco.2011.29.15_suppl.e14117DOI: 10.1200/jco.2011.29.15_suppl.e14117
Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). (Journal article)
Becerra, C., Salazar, R., Garcia-Carbonero, R., Thomas, A. L., Vázquez-Mazón, F., Cassidy, J., . . . Li, D. (2011). Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 29(15_suppl), 3525. doi:10.1200/jco.2011.29.15_suppl.3525DOI: 10.1200/jco.2011.29.15_suppl.3525
Stead, M., Cameron, D., Lester, N., Parmar, M., Haward, R., Kaplan, R., . . . National Cancer Research Networks across the UK. (2011). Strengthening clinical cancer research in the United Kingdom.. British journal of cancer, 104(10), 1529-1534. doi:10.1038/bjc.2011.69DOI: 10.1038/bjc.2011.69
Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): The MRC COIN trial experience. (Journal article)
Adams, R. A., James, M. D., Smith, C. G., Wilson, R. H., Fisher, D., Kenny, S. L., . . . Jasani, B. (2011). Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): The MRC COIN trial experience.. Journal of Clinical Oncology, 29(4_suppl), 359. doi:10.1200/jco.2011.29.4_suppl.359DOI: 10.1200/jco.2011.29.4_suppl.359
Chemotherapy for older patients with colorectal cancer – Authors' reply (Journal article)
Seymour, M. T., Thompson, L. C., O'Mahony, S., Brewster, A. E., Wasan, H. S., & Maughan, T. S. (2011). Chemotherapy for older patients with colorectal cancer – Authors' reply. The Lancet, 378(9793), 765-766. doi:10.1016/s0140-6736(11)61369-xDOI: 10.1016/s0140-6736(11)61369-x
Research-intensive cancer care in the NHS in the UK. (Journal article)
Cameron, D., Stead, M., Lester, N., Parmar, M., Haward, R., Maughan, T., . . . Selby, P. (2011). Research-intensive cancer care in the NHS in the UK.. Annals of oncology : official journal of the European Society for Medical Oncology, 22 Suppl 7, vii29-vii35. doi:10.1093/annonc/mdr423DOI: 10.1093/annonc/mdr423
2010
Jenkins, V., Farewell, D., Batt, L., Maughan, T., Branston, L., Langridge, C., . . . Fallowfield, L. (2010). The attitudes of 1066 patients with cancer towards participation in randomised clinical trials.. British journal of cancer, 103(12), 1801-1807. doi:10.1038/sj.bjc.6606004DOI: 10.1038/sj.bjc.6606004
Houlston, R. S., Cheadle, J., Dobbins, S. E., Tenesa, A., Jones, A. M., Howarth, K., . . . Tomlinson, I. P. M. (2010). Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.. Nature genetics, 42(11), 973-977. doi:10.1038/ng.670DOI: 10.1038/ng.670
Radiotherapy research priorities for the UK. (Journal article)
Maughan, T. S., Illidge, T. M., Hoskin, P., McKenna, W. G., Brunner, T. B., Stratford, I. J., . . . NCRI Clinical and Translational Radiotherapy Research Working Group. (2010). Radiotherapy research priorities for the UK.. Clinical oncology (Royal College of Radiologists (Great Britain)), 22(8), 707-709. doi:10.1016/j.clon.2010.03.006DOI: 10.1016/j.clon.2010.03.006
Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option. (Journal article)
Maughan, T., Adams, R., Wilson, R., Seymour, M., Meade, A., & Kaplan, R. (2010). Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(17), e275-e276. doi:10.1200/jco.2009.27.8218DOI: 10.1200/jco.2009.27.8218
A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. (Journal article)
Mukherjee, S., Hurt, C., Griffiths, G., Crosby, T., Staffurth, J., Bridges, S., . . . Maughan, T. S. (2010). A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer.. Journal of Clinical Oncology, 28(15_suppl), TPS222. doi:10.1200/jco.2010.28.15_suppl.tps222DOI: 10.1200/jco.2010.28.15_suppl.tps222
Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. (Journal article)
Maughan, T. S., Adams, R., Smith, C. G., Seymour, M. T., Wilson, R. H., Meade, A. M., . . . Kaplan, R. S. (2010). Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.. Journal of Clinical Oncology, 28(15_suppl), 3502. doi:10.1200/jco.2010.28.15_suppl.3502DOI: 10.1200/jco.2010.28.15_suppl.3502
Interim safety data on the ZICE trial: A randomized phase III, open-label, multicener, parallel group clinical trial to evaluate and compare the efficacy, safety profile, and tolerability of oral ibandronate versus intravenous zoledronate in the treatment of patients with breast cancer with bone metastases. (Journal article)
Barrett-Lee, P. J., Murray, N., Abraham, J., Casbard, A., Clements, H., Maughan, T. S., & Griffiths, G. (2010). Interim safety data on the ZICE trial: A randomized phase III, open-label, multicener, parallel group clinical trial to evaluate and compare the efficacy, safety profile, and tolerability of oral ibandronate versus intravenous zoledronate in the treatment of patients with breast cancer with bone metastases.. Journal of Clinical Oncology, 28(15_suppl), 1085. doi:10.1200/jco.2010.28.15_suppl.1085DOI: 10.1200/jco.2010.28.15_suppl.1085
Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial. (Journal article)
Adams, R., Wilson, R. H., Seymour, M. T., Meade, A. M., Madi, A., Cassidy, J., . . . Maughan, T. S. (2010). Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.. Journal of Clinical Oncology, 28(15_suppl), 3525. doi:10.1200/jco.2010.28.15_suppl.3525DOI: 10.1200/jco.2010.28.15_suppl.3525
2009
Griffiths, G. O., Burns, S., Noble, S. I., Macbeth, F. R., Cohen, D., & Maughan, T. S. (2009). FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.. BMC cancer, 9, 355. doi:10.1186/1471-2407-9-355DOI: 10.1186/1471-2407-9-355
Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. (Journal article)
Clements, D., Dhruva Rao, P., Ramanathan, D., Adams, R., Maughan, T. S., & Davies, M. M. (2009). Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 11(8), 845-848. doi:10.1111/j.1463-1318.2008.01695.xDOI: 10.1111/j.1463-1318.2008.01695.x
15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN) (Journal article)
Adams, R., Wilson, R., Seymour, M. T., Meade, A. M., Madi, A., Cassidy, J., . . . Maughan, T. S. (2009). 15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN). European Journal of Cancer Supplements, 7(3), 10. doi:10.1016/s1359-6349(09)72050-6DOI: 10.1016/s1359-6349(09)72050-6
6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN) (Journal article)
Maughan, T., Adams, R. A., Smith, C. G., Seymour, M. T., Wilson, R., Meade, A. M., . . . Kaplan, R. (2009). 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). European Journal of Cancer Supplements, 7(3), 4-5. doi:10.1016/s1359-6349(09)72034-8DOI: 10.1016/s1359-6349(09)72034-8
Impact of <i>K-ras</i> status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs) (Journal article)
Vale, C., Tierney, J. F., Meade, A., Fisher, D., Kaplan, R., Adams, R. A., . . . Parmar, M. K. (2009). Impact of <i>K-ras</i> status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs). Journal of Clinical Oncology, 27(15_suppl), 4122. doi:10.1200/jco.2009.27.15_suppl.4122DOI: 10.1200/jco.2009.27.15_suppl.4122
A new opportunity for radiotherapy research in the UK. (Journal article)
Maughan, T. S. (2009). A new opportunity for radiotherapy research in the UK.. Clinical oncology (Royal College of Radiologists (Great Britain)), 21(3), 157-158. doi:10.1016/j.clon.2008.12.007DOI: 10.1016/j.clon.2008.12.007
Adams, R. A., Meade, A. M., Madi, A., Fisher, D., Kay, E., Kenny, S., . . . Maughan, T. S. (2009). Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.. British journal of cancer, 100(2), 251-258. doi:10.1038/sj.bjc.6604877DOI: 10.1038/sj.bjc.6604877
2008
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. (Journal article)
Adams, R., Meade, A., Wasan, H., Griffiths, G., & Maughan, T. (2008). Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.. Expert review of anticancer therapy, 8(8), 1237-1245. doi:10.1586/14737140.8.8.1237DOI: 10.1586/14737140.8.8.1237
Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. (Journal article)
Mukherjee, S., Hudson, E., Reza, S., Thomas, M., Crosby, T., & Maughan, T. (2008). Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer.. Clinical oncology (Royal College of Radiologists (Great Britain)), 20(7), 535-540. doi:10.1016/j.clon.2008.02.003DOI: 10.1016/j.clon.2008.02.003
Funding cancer treatments: Ethics of PCT decision making on funding cancer treatments (Journal article)
Maughan, T. S., & Rule, J. (2008). Funding cancer treatments: Ethics of PCT decision making on funding cancer treatments. BMJ, 337(7666), 367-368.
Ethics of PCT decision making on funding cancer treatments. (Journal article)
Maughan, T. S., & Rule, J. (2008). Ethics of PCT decision making on funding cancer treatments.. BMJ (Clinical research ed.), 337, a1243. doi:10.1136/bmj.a1243DOI: 10.1136/bmj.a1243
Severe prolonged immunosuppression following fludarabine and rituximab combination therapy. (Journal article)
Hudson, E., Westmoreland, D., Gorman, C., Poynton, C. H., Lester, J. F., & Maughan, T. S. (2008). Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.. Chemotherapy, 54(3), 242-244. doi:10.1159/000140469DOI: 10.1159/000140469
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer (Journal article)
Moe, M., Micallef, R. A., Pwint, T., Maughan, T., Mort, D., & Wagstaff, J. (2008). Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer. Journal of Clinical Oncology, 26(15_suppl), 14623. doi:10.1200/jco.2008.26.15_suppl.14623DOI: 10.1200/jco.2008.26.15_suppl.14623
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. (Journal article)
Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J. -Y., Hecker, H., Stephens, R. J., . . . Köhne, C. -H. (2008). Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(9), 1443-1451. doi:10.1200/jco.2007.14.0509DOI: 10.1200/jco.2007.14.0509
Colon and rectum (Chapter)
Adams, R., Maughan, T., & Crosby, T. (2008). Colon and rectum. In Practical Clinical Oncology (pp. 159-173). Cambridge University Press. doi:10.1017/cbo9780511545375.014DOI: 10.1017/cbo9780511545375.014
Challenges in Colorectal Cancer (Book)
Scholefield, J. H., Grothey, A., Abcarian, H., & Maughan, T. (Eds.) (2006). Challenges in Colorectal Cancer. Wiley. doi:10.1002/9780470753231DOI: 10.1002/9780470753231
2007
O.10 Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2) (Journal article)
Seymour, M. T., Maughan, T. S., Wasan, H. S., Brewster, A. E., Shepherd, S. F., O'Mahoney, M. S., . . . Langley, R. E. (2007). O.10 Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2). Critical Reviews in Oncology/Hematology, 64, S32-S33. doi:10.1016/s1040-8428(13)70169-0DOI: 10.1016/s1040-8428(13)70169-0
8LB Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2) (Journal article)
Seymour, M. T., Maughan, T. S., Wasan, H. S., Brewster, A. E., Shepherd, S. F., O'Mahoney, M. S., . . . Langley, R. E. (2007). 8LB Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2). European Journal of Cancer Supplements, 5(6), 14. doi:10.1016/s1359-6349(07)70106-4DOI: 10.1016/s1359-6349(07)70106-4
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. (Journal article)
Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., . . . National Cancer Research Institute Colorectal Clinical Studies Group. (2007). Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.. Lancet (London, England), 370(9582), 143-152. doi:10.1016/s0140-6736(07)61087-3DOI: 10.1016/s0140-6736(07)61087-3
An audit of outcome of pancreatic cancer in a UK region: Does chemoradiation add to systemic chemotherapy for locally advanced disease (Journal article)
Hudson, E., Mukherjee, S., Reza, S., Thomas, M., Crosby, T., & Maughan, T. (2007). An audit of outcome of pancreatic cancer in a UK region: Does chemoradiation add to systemic chemotherapy for locally advanced disease. Journal of Clinical Oncology, 25(18_suppl), 15021. doi:10.1200/jco.2007.25.18_suppl.15021DOI: 10.1200/jco.2007.25.18_suppl.15021
Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial (Journal article)
Seymour, M. T., Maughan, T. S., Wasan, H. S., Brewster, A. E., Shepherd, S. F., O'Mahoney, M. S., . . . Langley, R. E. (2007). Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. Journal of Clinical Oncology, 25(18_suppl), 9030. doi:10.1200/jco.2007.25.18_suppl.9030DOI: 10.1200/jco.2007.25.18_suppl.9030
Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): Toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial (Journal article)
Maughan, T. (2007). Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): Toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial. Journal of Clinical Oncology, 25(18_suppl), 4070. doi:10.1200/jco.2007.25.18_suppl.4070DOI: 10.1200/jco.2007.25.18_suppl.4070
Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials (Journal article)
Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J. Y., Stephens, R. J., Van Cutsem, E., . . . Köhne, C. H. (2007). Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials. Journal of Clinical Oncology, 25(18_suppl), 4071. doi:10.1200/jco.2007.25.18_suppl.4071DOI: 10.1200/jco.2007.25.18_suppl.4071
A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. (Journal article)
Adams, R., Morgan, M., Mukherjee, S., Brewster, A., Maughan, T., Morrey, D., . . . Crosby, T. (2007). A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 33(3), 307-313. doi:10.1016/j.ejso.2006.10.026DOI: 10.1016/j.ejso.2006.10.026
Patterns of Recurrence after Definitive Chemo-radiotherapy for Oesophageal Carcinoma (Journal article)
Button, M. R., Morgan, C. A., Croydon, E. S., Brewster, A. E., Maughan, T. S., & Crosby, T. D. L. (2007). Patterns of Recurrence after Definitive Chemo-radiotherapy for Oesophageal Carcinoma. Clinical Oncology, 19(3), S25. doi:10.1016/j.clon.2007.01.343DOI: 10.1016/j.clon.2007.01.343
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. (Journal article)
Adams, R., & Maughan, T. (2007). Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.. Expert review of anticancer therapy, 7(4), 503-518. doi:10.1586/14737140.7.4.503DOI: 10.1586/14737140.7.4.503
Hudson, E., Powell, J., Mukherjee, S., Crosby, T. D. L., Brewster, A. E., Maughan, T. S., . . . Lester, J. F. (2007). Small cell oesophageal carcinoma: an institutional experience and review of the literature.. British journal of cancer, 96(5), 708-711. doi:10.1038/sj.bjc.6603611DOI: 10.1038/sj.bjc.6603611
Glynne-Jones, R., Falk, S., Maughan, T. S., Meadows, H. M., & Sebag-Montefiore, D. (2007). A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.. British journal of cancer, 96(4), 551-558. doi:10.1038/sj.bjc.6603570DOI: 10.1038/sj.bjc.6603570
2006
Cassidy, J., Douillard, J. -Y., Twelves, C., McKendrick, J. J., Scheithauer, W., Bustová, I., . . . Garrison, L. P. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.. British journal of cancer, 94(8), 1122-1129. doi:10.1038/sj.bjc.6603059DOI: 10.1038/sj.bjc.6603059
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. (Journal article)
Glynne-Jones, R., Sebag-Montefiore, D., Maughan, T. S., Falk, S. J., & McDonald, A. C. (2006). A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 17(1), 50-56. doi:10.1093/annonc/mdj031DOI: 10.1093/annonc/mdj031
2005
Shock and Awe (Journal article)
Maughan, T. (2005). Shock and Awe. Commercial Motor, 202(5158), 46-51.
Keys to success (Journal article)
Maughan, T. (2005). Keys to success. Commercial Motor, 202(5157), 64-65.
Small is beautiful (Journal article)
Maughan, T. (2005). Small is beautiful. Commercial Motor, 202(5157), 50-52.
In unity is strength (Journal article)
Maughan, T. (2005). In unity is strength. Commercial Motor, 202(5155), 50-52.
Information needs of cancer patients and its impact on patient outcomes (Journal article)
Salek, S., Al-Mohammadi, A., Nicholls, P. J., Maughan, T., & Mason, M. (2005). Information needs of cancer patients and its impact on patient outcomes. Journal of Applied Therapeutic Research, 5(4), 3-5.
Put out the right message (Journal article)
Maughan, T. (2005). Put out the right message. Commercial Motor, 202(5154), 64-65.
The wood from the trees (Journal article)
Maughan, T. (2005). The wood from the trees. Commercial Motor, 202(5153), 54-57.
Wheels within wheels (Journal article)
Maughan, T. (2005). Wheels within wheels. Commercial Motor, 202(5151), 52-57.
Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome. (Journal article)
Katugampola, R. P., Finlay, A. Y., Harper, J. I., Dojcinov, S., & Maughan, T. S. (2005). Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome.. The British journal of dermatology, 153(5), 1041-1046. doi:10.1111/j.1365-2133.2005.06839.xDOI: 10.1111/j.1365-2133.2005.06839.x
Sebag-Montefiore, D., Glynne-Jones, R., Falk, S., Meadows, H. M., & Maughan, T. (2005). A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.. British journal of cancer, 93(9), 993-998. doi:10.1038/sj.bjc.6602818DOI: 10.1038/sj.bjc.6602818
Retention attention (Journal article)
Maughan, T. (2005). Retention attention. Commercial Motor, 202(5150), 64-65.
Sky's the limit (Journal article)
Maughan, T. (2005). Sky's the limit. Commercial Motor, 202(5150), 52-55.
Waste not want not (Journal article)
Maughan, T. (2005). Waste not want not. Commercial Motor, 202(5148), 42-47.
Certified practitioners (Journal article)
Maughan, T. (2005). Certified practitioners. Commercial Motor, 202(5146), 64-65.
The prices is right! (Journal article)
Maughan, T. (2005). The prices is right!. Commercial Motor, 202(5145), 58-63.
The internet highway (Journal article)
Maughan, T. (2005). The internet highway. Commercial Motor, 202(5142), 64-65.
NG IT MPLE (Journal article)
Maughan, T. (2005). NG IT MPLE. Commercial Motor, 202(5141), 57-60.
Paper chase (Journal article)
Maughan, T. (2005). Paper chase. Commercial Motor, 202(5139), 48-52.
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. (Journal article)
Segaert, S., Tabernero, J., Chosidow, O., Dirschka, T., Elsner, J., Mancini, L., . . . Layton, A. (2005). The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 3(8), 599-606. doi:10.1111/j.1610-0387.2005.05058.xDOI: 10.1111/j.1610-0387.2005.05058.x
New horizons (Journal article)
Maughan, T. (2005). New horizons. Commercial Motor, 202(5138), 64-65.
Trailer parc (Journal article)
Maughan, T. (2005). Trailer parc. Commercial Motor, 202(5137), 40-43.
Eastern promise (Journal article)
Maughan, T. (2005). Eastern promise. Commercial Motor, 201(5135), 50-55.
The army game (Journal article)
Maughan, T. (2005). The army game. Commercial Motor, 201(5134), 24.
Danger money (Journal article)
Maughan, T. (2005). Danger money. Commercial Motor, 201(5133), 64-65.
Waisting away (Journal article)
Maughan, T. (2005). Waisting away. Commercial Motor, 201(5133), 22.
The route masters (Journal article)
Maughan, T. (2005). The route masters. Commercial Motor, 201(5132), 46-49.
The clothes show (Journal article)
Maughan, T. (2005). The clothes show. Commercial Motor, 201(5131), 50-55.
Preoperative radiation and irinotecan in combination with 5 fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer (LARC) (Journal article)
Sebag-Montefiore, D., Falk, S., Glynne-Jones, R., Maughan, T., & Meadows, H. M. (2005). Preoperative radiation and irinotecan in combination with 5 fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 23(16_suppl), 3576. doi:10.1200/jco.2005.23.16_suppl.3576DOI: 10.1200/jco.2005.23.16_suppl.3576
Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC) (Journal article)
Glynne-Jones, R., Sebag-Montefiore, D., Samuel, L., Falk, S., Maughan, T., & McDonald, A. (2005). Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 23(16_suppl), 3527. doi:10.1200/jco.2005.23.16_suppl.3527DOI: 10.1200/jco.2005.23.16_suppl.3527
Empire building (Journal article)
Maughan, T. (2005). Empire building. Commercial Motor, 201(5130), 50-53.
Fitting in (Journal article)
Maughan, T. (2005). Fitting in. Commercial Motor, 201(5129), 64.
The show must go on (Journal article)
Maughan, T. (2005). The show must go on. Commercial Motor, 201(5027), 56-61.
Travelling light (Journal article)
Maughan, T. (2005). Travelling light. Commercial Motor, 201(5026), 28-29.
Engineering your career (Journal article)
Maughan, T. (2005). Engineering your career. Commercial Motor, 201(5025), 64-65.
Fund managers (Journal article)
Maughan, T. (2005). Fund managers. Commercial Motor, 201(5024), 60-62.
Special forces (Journal article)
Maughan, T. (2005). Special forces. Commercial Motor, 201(5022), 84-87.
Honoured veterans (Journal article)
Maughan, T. (2005). Honoured veterans. Commercial Motor, 201(5020), 48-51.
Safety first (Journal article)
Maughan, T. (2005). Safety first. Commercial Motor, 201(5018), 54-59.
Concrete to cows (Journal article)
Maughan, T. (2005). Concrete to cows. Commercial Motor, 201(5017), 46-51.
Senior service (Journal article)
Maughan, T. (2005). Senior service. Commercial Motor, 201(5015), 56-61.
Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. (Journal article)
Hoskin, P. J., Smith, P., Maughan, T. S., Gilson, D., Vernon, C., Syndikus, I., . . . British National Lymphoma Investigation. (2005). Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma.. Clinical oncology (Royal College of Radiologists (Great Britain)), 17(1), 47-53. doi:10.1016/j.clon.2004.07.004DOI: 10.1016/j.clon.2004.07.004
Meet the extendibles (Journal article)
Maughan, T. (2005). Meet the extendibles. Commercial Motor, 201(5013), 60-65.
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. (Journal article)
Rea, D. W., Nortier, J. W. R., Ten Bokkel Huinink, W. W., Falk, S., Richel, D. J., Maughan, T., . . . Punt, C. J. A. (2005). A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 16(7), 1123-1132. doi:10.1093/annonc/mdi227DOI: 10.1093/annonc/mdi227
Does student teaching harm or help cancer patients? (Journal article)
Finlay, I., Maughan, T., & Williams, S. (2005). Does student teaching harm or help cancer patients?. Medical education, 39(11), 1166-1167. doi:10.1111/j.1365-2929.2005.02297.xDOI: 10.1111/j.1365-2929.2005.02297.x
Kenwright, S. (2005). The Assisted Dying for the Terminally Ill Bill 2004.. Clinical medicine (London, England), 5(2), 185. doi:10.7861/clinmedicine.5-2-185DOI: 10.7861/clinmedicine.5-2-185
2004
Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC) (Journal article)
Glynne-Jones, R., Sebag-Montefiore, D., McDonald, A., Falk, S., & Maughan, T. (2004). Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 22(14_suppl), 3575. doi:10.1200/jco.2004.22.14_suppl.3575DOI: 10.1200/jco.2004.22.14_suppl.3575
Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC) (Journal article)
Glynne-Jones, R., Sebag-Montefiore, D., McDonald, A., Falk, S., & Maughan, T. (2004). Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 22(14_suppl), 3575. doi:10.1200/jco.2004.22.90140.3575DOI: 10.1200/jco.2004.22.90140.3575
Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts) (Journal article)
Díaz-Rubio, E., Burris, H., Douillard, J. Y., Coxon, F. Y., Maughan, T., Bertetto, O., . . . Scheithauer, W. (2004). Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). Journal of Clinical Oncology, 22(14_suppl), 3737. doi:10.1200/jco.2004.22.90140.3737DOI: 10.1200/jco.2004.22.90140.3737
Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts) (Journal article)
Díaz-Rubio, E., Burris, H., Douillard, J. Y., Coxon, F. Y., Maughan, T., Bertetto, O., . . . Scheithauer, W. (2004). Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). Journal of Clinical Oncology, 22(14_suppl), 3737. doi:10.1200/jco.2004.22.14_suppl.3737DOI: 10.1200/jco.2004.22.14_suppl.3737
Brown, G., Davies, S., Williams, G. T., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., . . . Maughan, T. S. (2004). Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?. British journal of cancer, 91(1), 23-29. doi:10.1038/sj.bjc.6601871DOI: 10.1038/sj.bjc.6601871
Crosby, T. D. L., Brewster, A. E., Borley, A., Perschky, L., Kehagioglou, P., Court, J., & Maughan, T. S. (2004). Definitive chemoradiation in patients with inoperable oesophageal carcinoma.. British journal of cancer, 90(1), 70-75. doi:10.1038/sj.bjc.6601461DOI: 10.1038/sj.bjc.6601461
2003
The clinical impact of expert pathological review on lymphoma management: a regional experience. (Journal article)
Lester, J. F., Dojcinov, S. D., Attanoos, R. L., O'Brien, C. J., Maughan, T. S., Toy, E. T., & Poynton, C. H. (2003). The clinical impact of expert pathological review on lymphoma management: a regional experience.. British journal of haematology, 123(3), 463-468. doi:10.1046/j.1365-2141.2003.04629.xDOI: 10.1046/j.1365-2141.2003.04629.x
277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial (Journal article)
Punt, C. J. A., Nortier, J. W. R., ten Bokkel Huinink, W. W., Falk, S., Richel, D. J., Maughan, T., . . . Rea, D. W. (2003). 277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial. European Journal of Cancer Supplements, 1(5), S85. doi:10.1016/s1359-6349(03)90310-7DOI: 10.1016/s1359-6349(03)90310-7
Case report: Squamous carcinoma in an oesophageal foregut cyst. (Journal article)
Jacob, R., Hawkes, N. D., Dallimore, N., Butchart, E. G., Thomas, G. A. O., & Maughan, T. S. (2003). Case report: Squamous carcinoma in an oesophageal foregut cyst.. The British journal of radiology, 76(905), 343-346. doi:10.1259/bjr/30574796DOI: 10.1259/bjr/30574796
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. (Journal article)
Maughan, T. S., James, R. D., Kerr, D. J., Ledermann, J. A., Seymour, M. T., Topham, C., . . . Medical Research Council Colorectal Cancer Group. (2003). Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.. Lancet (London, England), 361(9356), 457-464. doi:10.1016/s0140-6736(03)12461-0DOI: 10.1016/s0140-6736(03)12461-0
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. (Journal article)
Cascinu, S., Georgoulias, V., Kerr, D., Maughan, T., Labianca, R., & Ychou, M. (2003). Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.. Annals of oncology : official journal of the European Society for Medical Oncology, 14 Suppl 2, ii25-ii29. doi:10.1093/annonc/mdg725DOI: 10.1093/annonc/mdg725
2002
RANDOMIZED TRIAL OF THREE CHEMOTHERAPY REGIMENS FOR ADVANCED COLORECTAL CANCER (Journal article)
Berlin, J. D. (2002). RANDOMIZED TRIAL OF THREE CHEMOTHERAPY REGIMENS FOR ADVANCED COLORECTAL CANCER. Evidence-Based Gastroenterology, 3(3), 84-85. doi:10.1097/00132579-200208000-00006DOI: 10.1097/00132579-200208000-00006
Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., . . . Fielding, J. W. L. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.. British journal of cancer, 86(12), 1864-1870. doi:10.1038/sj.bjc.6600310DOI: 10.1038/sj.bjc.6600310
Hale, J. P., Cohen, D. R., Maughan, T. S., & Stephens, R. J. (2002). Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.. British journal of cancer, 86(11), 1684-1690. doi:10.1038/sj.bjc.6600273DOI: 10.1038/sj.bjc.6600273
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. (Journal article)
Maughan, T. S., James, R. D., Kerr, D. J., Ledermann, J. A., McArdle, C., Seymour, M. T., . . . British MRC Colorectal Cancer Working Party. (2002). Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.. Lancet (London, England), 359(9317), 1555-1563. doi:10.1016/s0140-6736(02)08514-8DOI: 10.1016/s0140-6736(02)08514-8
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. (Journal article)
Keating, M. J., Cazin, B., Coutré, S., Birhiray, R., Kovacsovics, T., Langer, W., . . . Hérait, P. (2002). Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20(1), 205-213. doi:10.1200/jco.2002.20.1.205DOI: 10.1200/jco.2002.20.1.205
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials. (Journal article)
Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T. S., . . . Facchini, T. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.. European journal of cancer (Oxford, England : 1990), 38(4), 478-486. doi:10.1016/s0959-8049(01)00413-0DOI: 10.1016/s0959-8049(01)00413-0
2001
Maughan, T. S. (2001). Adjuvant chemotherapy for colorectal cancer.. British journal of cancer, 85(10), 1422-1424. doi:10.1054/bjoc.2001.2081DOI: 10.1054/bjoc.2001.2081
Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial (Journal article)
Maughan, T. S., James, R. J., Kerr, D. J., Ledermann, J., McArdle, C., Seymour, M., . . . Stephens, R. J. (2001). Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial. European Journal of Cancer, 37, S271. doi:10.1016/s0959-8049(01)81493-3DOI: 10.1016/s0959-8049(01)81493-3
Portfolio learning with cancer patients: an integrated module in undergraduate medical education. (Journal article)
Maughan, T. S., Finlay, I. G., & Webster, D. J. (2001). Portfolio learning with cancer patients: an integrated module in undergraduate medical education.. Clinical oncology (Royal College of Radiologists (Great Britain)), 13(1), 44-49. doi:10.1053/clon.2001.9213DOI: 10.1053/clon.2001.9213
2000
Anderson, H., Hopwood, P., Stephens, R. J., Thatcher, N., Cottier, B., Nicholson, M., . . . Carmichael, J. (2000). Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.. British journal of cancer, 83(4), 447-453. doi:10.1054/bjoc.2000.1307DOI: 10.1054/bjoc.2000.1307
1999
Endosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe. (Journal article)
Bowrey, D. J., Clark, G. W., Roberts, S. A., Maughan, T. S., Hawthorne, A. B., Williams, G. T., & Carey, P. D. (1999). Endosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe.. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 12(4), 258-263. doi:10.1046/j.1442-2050.1999.00071.xDOI: 10.1046/j.1442-2050.1999.00071.x
Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. (Journal article)
Bowrey, D. J., Clark, G. W., Roberts, S. A., Hawthorne, A. B., Maughan, T. S., Williams, G. T., & Carey, P. D. (1999). Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus.. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 3(5), 462-467. doi:10.1016/s1091-255x(99)80098-5DOI: 10.1016/s1091-255x(99)80098-5
1998
Clinical and endoscopic response to neoadjuvant therapy for carcinoma of the esophagus (Journal article)
Bowrey, D. J., Clark, G. W. B., Roberts, S. A., Maughan, T. S., Hawthorne, A. B., & Carey, P. D. (1998). Clinical and endoscopic response to neoadjuvant therapy for carcinoma of the esophagus. Gastroenterology, 114, A568. doi:10.1016/s0016-5085(98)82311-1DOI: 10.1016/s0016-5085(98)82311-1
A randomized controlled study of portfolio learning in undergraduate cancer education. (Journal article)
Finlay, I. G., Maughan, T. S., & Webster, D. J. (1998). A randomized controlled study of portfolio learning in undergraduate cancer education.. Medical education, 32(2), 172-176. doi:10.1046/j.1365-2923.1998.00160.xDOI: 10.1046/j.1365-2923.1998.00160.x
Combined modality treatment in oesophageal carcinoma. (Journal article)
Maughan, T. S., & Crosby, T. D. (1998). Combined modality treatment in oesophageal carcinoma.. Clinical oncology (Royal College of Radiologists (Great Britain)), 10(6), 354-355. doi:10.1016/s0936-6555(98)80028-9DOI: 10.1016/s0936-6555(98)80028-9
Judson, I., Maughan, T., Beale, P., Primrose, J., Hoskin, P., Hanwell, J., . . . Sutcliffe, F. (1998). Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).. British journal of cancer, 78(9), 1188-1193. doi:10.1038/bjc.1998.652DOI: 10.1038/bjc.1998.652
1997
OP13. Economics of the MRC colorectal working party CR06 trial (Journal article)
Hale, J., Cohen, D., & Maughan, T. (1997). OP13. Economics of the MRC colorectal working party CR06 trial. European Journal of Cancer, 33, S5. doi:10.1016/s0959-8049(97)85892-3DOI: 10.1016/s0959-8049(97)85892-3
24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC) (Journal article)
Anderson, H., Cottier, B., Nicolson, M., Milroy, R., Maughan, T., Bond, M., . . . Thatcher, N. (1997). 24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 18, 9. doi:10.1016/s0169-5002(97)89303-8DOI: 10.1016/s0169-5002(97)89303-8
Johnson, R. C., Fligelstone, L. J., Wheeler, M. H., Horgan, K., & Maughan, T. S. (1997). Laparoscopic cholecystectomy: incidental carcinoma of the gallbladder with abdominal wall and axillary node metastasis.. HPB surgery : a world journal of hepatic, pancreatic and biliary surgery, 10(3), 169-171. doi:10.1155/1997/60975DOI: 10.1155/1997/60975
1996
Melcher, A. A., Mort, D., & Maughan, T. S. (1996). Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.. British journal of cancer, 74(10), 1651-1654. doi:10.1038/bjc.1996.604DOI: 10.1038/bjc.1996.604
1995
1119 Glycyl-glutamine supplemention and high dose therapy (Journal article)
Maughan, T. S., Poynton, C. H., Hanson, J., Shelley, M., Jebb, S., & Elya, M. (1995). 1119 Glycyl-glutamine supplemention and high dose therapy. European Journal of Cancer, 31, S234. doi:10.1016/0959-8049(95)96365-kDOI: 10.1016/0959-8049(95)96365-k
Hanna, C. L., McKinna, F. E., Williams, L. B., Morrey, D., Adams, M., Mason, M. D., & Maughan, T. S. (1995). High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.. British journal of cancer, 72(3), 774-776. doi:10.1038/bjc.1995.409DOI: 10.1038/bjc.1995.409
1994
Basic principles of radiotherapy for surgical oncologists. 6--Patient selection. (Journal article)
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 6--Patient selection.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(6), 705-710.
Minimally invasive surgery. May disseminate undiagnosed tumor. (Journal article)
Johnson, R. C., Fligelstone, L. J., & Maughan, T. S. (1994). Minimally invasive surgery. May disseminate undiagnosed tumor.. BMJ (Clinical research ed.), 308(6922), 199. doi:10.1136/bmj.308.6922.199DOI: 10.1136/bmj.308.6922.199
Jebb, S. A., Osborne, R. J., Maughan, T. S., Mohideen, N., Mack, P., Mort, D., . . . Elia, M. (1994). 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.. British journal of cancer, 70(4), 732-735. doi:10.1038/bjc.1994.385DOI: 10.1038/bjc.1994.385
Basic principles of radiotherapy for surgical oncologists. 1--Effects of radiotherapy on superficial tissues. Implications for treating skin cancer. (Journal article)
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 1--Effects of radiotherapy on superficial tissues. Implications for treating skin cancer.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(1), 74-79.
Basic principles of radiotherapy for surgical oncologists. 2--Effects of radiotherapy on deeper tissues as illustrated by the treatment of breast cancer. (Journal article)
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 2--Effects of radiotherapy on deeper tissues as illustrated by the treatment of breast cancer.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(2), 168-174.
Basic principles of radiotherapy for surgical oncologists. 4--Fractions, photons and the future. (Journal article)
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 4--Fractions, photons and the future.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(4), 484-492.
Bone marrow scintigraphy in small cell carcinoma of the lung. (Journal article)
Li, D. J., Maughan, T. S., Miles, K. A., & Wraight, E. P. (1994). Bone marrow scintigraphy in small cell carcinoma of the lung.. Nuclear medicine communications, 15(1), 29-33. doi:10.1097/00006231-199401000-00006DOI: 10.1097/00006231-199401000-00006
Portfolio learning: a proposal for undergraduate cancer teaching. (Journal article)
Finlay, I. G., Maughan, T. S., & Webster, D. J. (1994). Portfolio learning: a proposal for undergraduate cancer teaching.. Medical education, 28(1), 79-82. doi:10.1111/j.1365-2923.1994.tb02690.xDOI: 10.1111/j.1365-2923.1994.tb02690.x
1993
Polychemotherapy in advanced non-small-cell lung cancer. (Journal article)
Rodger, A. (1993). Polychemotherapy in advanced non-small-cell lung cancer.. Lancet (London, England), 342(8873), 740-741. doi:10.1016/0140-6736(93)91733-3DOI: 10.1016/0140-6736(93)91733-3
Adverse reactions to Campath-1H monoclonal antibody. (Journal article)
Poynton, C. H., Mort, D., & Maughan, T. S. (1993). Adverse reactions to Campath-1H monoclonal antibody.. Lancet (London, England), 341(8851), 1037. doi:10.1016/0140-6736(93)91139-dDOI: 10.1016/0140-6736(93)91139-d
Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer. (Journal article)
Falk, S. J., Maughan, T. S., Laurence, V. M., Lamont, A., Boote, D., Ford, J. M., . . . Bleehen, N. M. (1993). Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer.. Clinical oncology (Royal College of Radiologists (Great Britain)), 5(2), 85-88. doi:10.1016/s0936-6555(05)80852-0DOI: 10.1016/s0936-6555(05)80852-0
1992
The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. (Journal article)
Wraight, E. P., Bard, D. R., Maughan, T. S., Knight, C. G., & Page-Thomas, D. P. (1992). The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma.. The British journal of radiology, 65(770), 112-118. doi:10.1259/0007-1285-65-770-112DOI: 10.1259/0007-1285-65-770-112
The Use of Derivatives of α-MSH for Targeting to Melanomas In Vivo (Chapter)
Bard, D. R., Knight, C. G., Page-Thomas, D. P., Wraight, E. P., & Maughan, T. S. (1992). The Use of Derivatives of α-MSH for Targeting to Melanomas In Vivo. In Targeting of Drugs 3 (pp. 1-8). Springer US. doi:10.1007/978-1-4615-2938-5_1DOI: 10.1007/978-1-4615-2938-5_1
Maughan, T. S., Ward, R., Dennis, I., Honess, D. J., Workman, P., & Bleehen, N. M. (1992). Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.. British journal of cancer, 66(3), 579-582. doi:10.1038/bjc.1992.317DOI: 10.1038/bjc.1992.317
1991
The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study. (Journal article)
Bleehen, N. M., Maughan, T. S., Workman, P., Newman, H. F., Stenning, S., & Ward, R. (1991). The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 20 Suppl 1, 137-142. doi:10.1016/0167-8140(91)90201-qDOI: 10.1016/0167-8140(91)90201-q
1990
Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508). (Journal article)
Maughan, T. S., Newman, H. F., Bleehen, N. M., Ward, R., & Workman, P. (1990). Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).. International journal of radiation oncology, biology, physics, 18(5), 1151-1156. doi:10.1016/0360-3016(90)90452-pDOI: 10.1016/0360-3016(90)90452-p
OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment. (Journal article)
Maughan, T. S., Haylock, B., Hayward, M., Facey, P., Evans, W. D., Shelley, M. D., . . . Adams, M. (1990). OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment.. Clinical oncology (Royal College of Radiologists (Great Britain)), 2(4), 199-205. doi:10.1016/s0936-6555(05)80168-2DOI: 10.1016/s0936-6555(05)80168-2
1989
A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). (Journal article)
Bleehen, N. M., Newman, H. F., Maughan, T. S., & Workman, P. (1989). A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).. International journal of radiation oncology, biology, physics, 16(4), 1093-1096. doi:10.1016/0360-3016(89)90924-3DOI: 10.1016/0360-3016(89)90924-3
Maughan, T. S., Fish, R. G., Shelley, M. D., Jasani, B., Williams, G. T., & Adams, M. (1989). CA125 in ovarian tumour tissue at second laparotomy.. British journal of cancer, 59(2), 259-260. doi:10.1038/bjc.1989.54DOI: 10.1038/bjc.1989.54
Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment. (Journal article)
Workman, P., Ward, R., Maughan, T. S., Newman, H. F., & Bleehen, N. M. (1989). Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.. International journal of radiation oncology, biology, physics, 17(1), 177-181. doi:10.1016/0360-3016(89)90386-6DOI: 10.1016/0360-3016(89)90386-6
Kerr, D. J., Maughan, T., Newlands, E., Rustin, G., Bleehen, N. M., Lewis, C., & Kaye, S. B. (1989). Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.. British journal of cancer, 60(1), 104-106. doi:10.1038/bjc.1989.230DOI: 10.1038/bjc.1989.230
1988
Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary. (Journal article)
Maughan, T. S., Fish, R. G., Shelley, M., Jasani, B., Williams, G. T., & Adams, M. (1988). Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.. Gynecologic oncology, 30(3), 342-346. doi:10.1016/0090-8258(88)90248-xDOI: 10.1016/0090-8258(88)90248-x
1987
The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy. (Journal article)
Fish, R. G., Shelley, M. D., Maughan, T., Rocker, I., & Adams, M. (1987). The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.. European journal of cancer & clinical oncology, 23(6), 831-835. doi:10.1016/0277-5379(87)90287-2DOI: 10.1016/0277-5379(87)90287-2
1984
Infants in Juba, southern Sudan: the first twelve months of life. (Journal article)
Woodruff, A. W., Adamson, E. A., Suni, A. E., Maughan, T. S., Kaku, M., & Bundru, N. (1984). Infants in Juba, southern Sudan: the first twelve months of life.. Lancet (London, England), 2(8401), 506-509. doi:10.1016/s0140-6736(84)92577-7DOI: 10.1016/s0140-6736(84)92577-7
1983
Round the World (Journal article)
Maughan, T. S., & Lorenz, W. (1983). Round the World. The Lancet, 322(8357), 1016-1017. doi:10.1016/s0140-6736(83)90991-1DOI: 10.1016/s0140-6736(83)90991-1
